

11-24-00

Box seq.

A

11/22/00

jc945 U.S. PTO

Please type a plus sign (+) inside this box → ☐PTO/SB/05 (4/98)
Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. 6633.US.O2

First Inventor or Application Identifier Fortuna Haviv

Title PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY

Express Mail Label No. EL384167558US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

1. ☒ * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Specification [Total Pages 76]
(preferred arrangement set forth below)
- Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☐ Drawing(s) (35 U.S.C. 113) [Total Sheets]
4. Oath or Declaration [Total Pages]
- a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 16 completed)
 - i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

* NOTE FOR ITEMS 1 & 13 IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

5. ☐ Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☒ Computer Readable Copy
 - b. ☒ Paper Copy (identical to computer copy)
 - c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment Papers (cover sheet & document(s))
8. ☐ 37 C.F.R. § 3.73(b) Statement of Power of Attorney (when there is an assignee)
9. ☐ English Translation Document (if applicable)
10. ☐ Information Disclosure Statement (IDS)/PTO-1449 [Copies of IDS Citations]
11. ☐ Preliminary Amendment
12. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
13. ☐ * Small Entity Statement(s) [Statement filed in prior application (PTO/SB/09-12) Status still proper and desired]
14. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
15. ☒ Other: Application Cover Sheet

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: /

Prior application information: Examiner Group / Art Unit:

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS☐ Customer Number or Bar Code Label:

(Insert Customer No. or Attach bar code label here)

or ☒ Correspondence address below

Name Steven F. Weinstock
Abbott Laboratories
Department 377 / AP6D-2
Address 100 Abbott Park Road
City Abbott Park State IL Zip Code 60064-6050
Country USA Telephone (847) 937-3810 Fax (847) 938-2623

Name (Print/Type) B. Gregory Donner Registration No. (Attorney/Agent) 34,580
Signature B. Gregory Donner Date Nov 21, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.
These are the fees effective October 1, 1997
Small Entity payments must be supported by a small entity statement,
otherwise large entity fees must be paid See Forms PTO/SB/09-12
See 37 C.F.R. §§1.27 and 1.28

TOTAL AMOUNT OF PAYMENT (\$ 890.00

Complete if Known

Application Number
Filing Date November 22, 2000
First Named Inventor Fortuna Haviv
Examiner Name (not yet assigned)
Group / Art Unit (not yet assigned)
Attorney Docket No. 6633.US.O2



METHOD OF PAYMENT (check one)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:
Deposit Account Number 01-0025
Deposit Account Name Abbott Laboratories
☒ Charge Any Additional Fee Required Under 37 C.F.R. §§ 1.16 and 1.17 ☐ Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance

2. ☐ Payment Enclosed:
☐ Check ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	790	201	395	Utility filing fee	710.00
106	330	206	165	Design filing fee	
107	540	207	270	Plant filing fee	
108	790	208	395	Reissue filing fee	
114	150	214	75	Provisional filing fee	
SUBTOTAL (1)					(\$ 710.00

2. EXTRA CLAIM FEES

Total Claims	Extra Claims	Fee from below	Fee Paid
30	20** = 10	18.00	180.00
3	3** = 0	80.00	00.00
Multiple Dependent			

**or number previously paid, if greater; For Reissues, see below

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
103	22	203	11	Claims in excess of 20
102	82	202	41	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim, if not paid
109	82	209	41	** Reissue independent claims over original patent
110	22	210	11	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 180.00

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet.	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	950	217	475	Extension for reply within third month	
118	1,510	218	755	Extension for reply within fourth month	
128	2,060	228	1,030	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,320	241	660	Petition to revive - unintentional	
142	1,320	242	660	Utility issue fee (or reissue)	
143	450	243	225	Design issue fee	
144	670	244	335	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	790	246	395	Filing a submission after final rejection (37 CFR 1.129(a))	
149	790	249	395	For each additional invention to be examined (37 CFR 1.129(b))	

Other fee (specify) _____

Other fee (specify) _____

* Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0

SUBMITTED BY

Typed or Printed Name B. Gregory Donner

Signature

B. Gregory Donner

Date 11/21/00

Complete (if applicable)

Reg. Number 34,580

Deposit Account User ID

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SEQUENCE LISTING

<110> Abbott Laboratories
Haviv, Fortuna
Henkin, Jack
Bradley, Michael F.
Kalvin, Douglas M.
Schneider, Andrew J.

<120> PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY

<130> 6633.US.02

<150> US 60/166,791

<151> 1999-11-22

<160> 1

<170> FastSEQ for Windows Version 4.0

 $\langle 210 \rangle$ 1

<211> 11

<212> PRT

<213> Antiangiogenic Peptide

<220>

<221> VARIANT

$$\langle 222 \rangle \quad (1) \dots (1)$$

<223> Xaa = R1-(CH₂)_n-C(O)- wherein R is N-acetylamino
at position 1

<221> VARIANT

 $\langle 222 \rangle \quad (2) \dots (2)$

<223> Xaa = Ala, B-Ala , Asn, Cit, Gly(Et), Gln, Glu,
Met, N-MeAla, N-MePro, Pro, Glu(pyro), and Sar at
position 2

<221> VARIANT

 $\langle 222 \rangle \quad (2) \dots (2)$

<223> Xaa = Ser, Thr, H3C-C(O)-HN-(CH₂)_q-C(O)-, wherein
q is an integer, and
H3C-C(O)-HN-CH₂CH₂-O-(CH₂CH₂O)_r-CH₂-C(O)-, wherein
r is an integer at position 2

<221> VARIANT

 $\langle 222 \rangle \quad (3) \dots (3)$

<223> Xaa = Ala, Asn, Asp, Gln, Glu, Gly, Leu, Met,
PheAla, Pro, and Ser at position 3

<221> VARIANT

<222> (4) . . . (4)

<223> Xaa = AlloIle, AllylGly, 2-Abu, (1R,4S)AmCyeCO,
Asp, 5-BrThiAla, 3-ClPheAla, 4-ClPheAla,
3-CNPheAla, Cys(Et), Cys(Me), 2,3-Diapr,
2,4-Diabu, 3,4-diOMePheAla at position 4

<221> VARIANT

```
<223> Xaa = 2-Abu, Aib, Gly(t-Bu), HPro, OHPro, Ile,
      Leu, PheAla, Pro, Ser, Tic, Thr, and Val at
      position 10
```

 $\langle 222 \rangle \quad (11) \dots (11)$

<223> Xaa = AzaGlyNH2, GlyNH2, GlyNH-ethyl, SarNH2, and SerNH2 at position 11

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY

Cross-Reference to Related Applications

5 This application claims priority to the provisional U.S. Patent Application Serial No. 60/166,791, filed November 22, 1999.

Technical Field

10 The invention relates to novel compounds having activity useful for treating conditions which arise or are exacerbated by angiogenesis, pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of inhibiting angiogenesis.

Background of the Invention

15 Angiogenesis is the fundamental process by which new blood vessels are formed and is essential to a variety of normal body activities (such as reproduction, development and wound repair). Although the process is not completely understood, it is believed to involve a complex interplay of molecules which both stimulate and inhibit the growth of endothelial cells, the primary cells of the capillary blood vessels. Under normal
20 conditions these molecules appear to maintain the microvasculature in a quiescent state (i.e., one of no capillary growth) for prolonged periods that may last for weeks, or in some cases, decades. However, when necessary, such as during wound repair, these same cells can undergo rapid proliferation and turnover within as little as five days (Folkman, J. and Shing, Y., *The Journal of Biological Chemistry*, **267(16)**: 10931-10934, and Folkman, J.
25 and Klagsbrun, M., *Science*, **235**: 442-447 (1987)).

 Although angiogenesis is a highly regulated process under normal conditions, many diseases (characterized as "angiogenic diseases") are driven by persistent unregulated angiogenesis. Otherwise stated, unregulated angiogenesis may either cause a particular disease directly or exacerbate an existing pathological condition. For example,
30 ocular neovascularization has been implicated as the most common cause of blindness. In certain existing conditions such as arthritis, newly formed capillary blood vessels invade the joints and destroy cartilage. In diabetes, new capillaries formed in the retina invade the vitreous, bleed, and cause blindness. Growth and metastasis of solid tumors are also angiogenesis-dependent (Folkman, J., *Cancer Research*, **46**: 467-473 (1986), Folkman, J.,
35 *Journal of the National Cancer Institute*, **82**: 4-6 (1989)). It has been shown, for example, that tumors which enlarge to greater than 2 mm, must obtain their own blood supply and

$R^2-CH_2CH_2-O-(CH_2CH_2O)_p-CH_2-C(O)-$, wherein p is an integer from 1 to 8 and R^2 is selected from the group consisting of hydrogen, N-acetylamino, and alkyl;

5 Xaa₂ is an amino acyl residue selected from the group consisting of
alanyl,
β-alanyl,
asparaginyll,
citrullyl,
10 N-ethylglycyl,
glutaminyl,
glutamyl,
methionyl,
N-methylalanyl,
15 N-methylprolyl,
prolyl,
pyro-glutamyl,
sarcosyl,
seryl,
20 threonyl,
 $H_3C-C(O)-HN-(CH_2)_q-C(O)-$, wherein q is an integer from 1 to 8, and
 $H_3C-C(O)-HN-CH_2CH_2-O-(CH_2CH_2O)_r-CH_2-C(O)-$, wherein r is an integer
from 1 to 8;
with the proviso that Xaa₁ is absent when Xaa₂ is N-methylprolyl, $H_3C-C(O)-$
25 $HN-(CH_2)_q-C(O)-$, or $H_3C-C(O)-HN-CH_2CH_2-O-(CH_2CH_2O)_r-CH_2-C(O)-$;

Xaa₃ is an amino acyl residue selected from the group consisting of
alanyl,
asparaginyll,
30 aspartyl,
glutaminyl,
glutamyl,
glycyl,
leucyl,
35 methionyl,
phenylalanyl,

do so by inducing the growth of new capillary blood vessels. Once these new blood vessels become embedded in the tumor, they provide a means for tumor cells to enter the circulation and metastasize to distant sites, such as the liver, the lung, and the bones (Weidner, N., et. al., *The New England Journal of Medicine*, **324**(1): 1-8 (1991)).

5 Several angiogenesis inhibitors are currently under development for use in treating angiogenic diseases (Gasparini, G. and Harris, A.L., *J Clin Oncol* **13**(3): 765-782, (1995)). A number of disadvantages have been associated with many of these compounds. A potent angiogenesis inhibitor, for example suramin, can cause severe systemic toxicity in humans at doses required to reach antitumor activity. Other compounds, such as retinoids, 10 interferons, and antiestrogens are safe for human use, but have only a weak anti-angiogenic effect.

 A novel class of compounds having particularly effective *in vitro* and *in vivo* angiogenesis inhibiting properties, as well as a promising toxicity profile, has been described in commonly-owned U.S. Patent Application Ser. No. 09/316,888, filed May 21, 15 1999. Copending provisional U.S. Patent Application Ser. No. 60/166,924, filed November 22, 1999, describes N-alkylated peptides having enhanced stability against *in vivo* enzymatic cleavage, improved pharmacokinetics, and increased water solubility. Although peptidic compounds inhibiting angiogenesis have been described, it would be desirable to prepare analogs having a favorable toxicity profile which also exhibit 20 improved angiogenesis inhibiting properties.

Summary of the Invention

 The present invention relates to a novel class of peptidic compounds exhibiting antiangiogenic activity. Compounds of the present invention generally have unnatural 25 amino acids in the 3-position of the peptide. The residues in position 3 are structurally novel and can be neutral or charged. The novel substitution of the amino acyl residues in the 3-position of the peptide affords compounds having enhanced properties of angiogenesis inhibition.

 In one aspect, the present invention provides a compound of formula (I)

30 $Xaa_1-Xaa_2-Xaa_3-Xaa_4-Xaa_5-Xaa_6-Xaa_7-Xaa_8-Xaa_9-Xaa_{10}-Xaa_{11}$ (I), (SEQ ID NO:1)

 or a pharmaceutically acceptable salt thereof, wherein

Xaa_1 is absent or Xaa_1 is selected from the group consisting of hydrogen and an acyl group, wherein the acyl group is selected from the group consisting of $R^1-(CH_2)_n-C(O)-$, wherein n is an integer from 0 to 8 and R^1 is selected from 35 the group consisting of N-acetylamino, alkoxy, alkyl, aryl, carboxy, cycloalkenyl, cycloalkyl, heterocycle, hydroxy; and

prolyl, and
seryl;

Xaa₄ is an amino acyl residue selected from the group consisting of

- 5 alloisoleucyl,
- allylglycyl,
- 2-aminobutyryl,
- (1R,4S)-1-aminocyclopent-2-ene-4-carbonyl,
- aspartyl,
- 10 3-(5-bromothien-2-yl)alanyl,
- 3-(3-chlorophenyl)alanyl,
- 3-(4-chlorophenyl)alanyl,
- 3-(3-cyanophenyl)alanyl,
- cysteinyl(S-ethyl),
- 15 cysteinyl(S-methyl),
- 2,4-diaminobutanoyl,
- 2,3-diaminopropionyl,
- 3-(3,4-dimethoxyphenyl)alanyl,
- 3-(3-fluorophenyl)alanyl,
- 20 3-(4-fluorophenyl)alanyl,
- histidyl,
- homophenylalanyl,
- homoseryl,
- lysyl(N-epsilon-acetyl),
- 25 methionyl(sulfone),
- methionyl(sulfoxide),
- 3-(4-methylphenyl)alanyl,
- 3-(naphth-1-yl)alanyl,
- 3-(naphth-2-yl)alanyl,
- 30 ornithyl,
- phenylglycyl,
- prolyl,
- 3-(3-pyridyl)alanyl,
- seryl(O-benzyl),
- 35 styrylalanyl,
- 1,2,3,4-tetrahydroisoquinoline-3-carbonyl,

3-(thiazolyl)alanyl,
3-(thien-2-yl)alanyl,
D-3-(thien-2-yl)alanyl,
tryptyl,
5 tyrosyl, and
D-valyl;

Xaa₅ is an amino acyl residue selected from the group consisting of

10 D-alanyl,
alloisoleucyl,
D-alloisoleucyl,
D-allothreonyl,
D-allylglycyl,
D-2-aminobutyryl,
15 D-3-(4-aminophenyl)alanyl,
D-asparaginyll,
D-aspartyl,
D-3-(4,4'-biphenyl)alanyl,
D-*t*-butylglycyl,
20 D-3-(4-chlorophenyl)alanyl,
D-citrullyl,
D-3-(3-cyanophenyl)alanyl,
D-cyclohexylalanyl,
D-cyclohexylglycyl,
25 D-cysteinyl,
D-cysteinyl(S-*t*-butyl),
dehydroleucyl,
D-3-(3,4-difluorophenyl)alanyl,
D-3-(3,4-dimethoxyphenyl)alanyl,
30 D-glutaminyll,
D-glutamyl,
glycyl,
D-histidyl,
D-homoisoleucyl,
35 D-homophenylalanyl,
D-homoseryl,

threonyl,
tryptyl,
tyrosyl, and
valyl;

5

Xaa₈ is an amino acyl residue selected from the group consisting of

alanyl,
alloisoleucyl,
D-alloisoleucyl,
allylglycyl,
aspartyl,
t-butylglycyl,
citrullyl,
cyclohexylglycyl,
cysteinyll,
glutamyl,
glycyl,
homoseryl,
isoleucyl,
D-isoleucyl,
leucyl,
lysyl(N-epsilon-acetyl),
methionyl,
3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
norvalyl,
penicillaminyll,
phenylalanyl,
prolyl,
seryl,
tryptyl,
tyrosyl, and
valyl;

10

15

20

25

30

35

Xaa₉ is an amino acyl residue selected from
[(4-amino(N-isopropyl)methyl)phenyl]alanyl,

3-(4-amino-N-isopropylphenyl)alanyl,
 arginyl,
 arginyl(N^GN^{G'}diethyl),
 citrullyl,
 5 3-(cyclohexyl)alanyl(4-N-isopropyl),
 glycyl[4-piperidiny(N-amidino)],
 (3-guanidino)alanyl,
 3-(4-guanidinophenyl)alanyl,
 histidyl,
 10 homoarginyl,
 lysyl,
 lysyl(N-epsilon-isopropyl),
 lysyl(N-epsilon-nicotinyl),
 norarginyl,
 15 ornithyl(N-delta-isopropyl),
 ornithyl(N-delta-nicotinyl),
 ornithyl[N-delta-(2-imidazoliny)],
 [4-piperidiny(N-amidino)]alanyl, and
 [3-pyrrolidiny(2-N-amidino)]alanyl;

20 Xaa₁₀ is an amino acyl residue selected from the group consisting of
 D-alanyl,
 2-aminobutyryl,
 2-aminoisobutyryl,
 25 *t*-butylglycyl,
 homopropyl,
 hydroxypropyl,
 isoleucyl,
 leucyl,
 30 phenylalanyl,
 prolyl,
 D-prolyl,
 seryl,
 1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
 35 threonyl, and
 valyl;

Xaa₁₁ is a hydroxy group or an amino acid amide selected from the group consisting of

D-alanylamide,

D-alanylethylamide,

azaglycylamide,

glycylamide,


glycylethylamide,

sarcosylamide,

serylamide,

D-serylamide,

a residue represented by the formula



a group represented by the formula $-\text{NH}-\text{R}^5$; wherein

s is an integer selected from 0 to 8;

R³ is selected from the group consisting of hydrogen, alkyl, and a 5- to 6-membered cycloalkyl ring;

R⁴ is selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, cycloalkenyl, cycloalkyl, heterocycle, and hydroxy;

provided that s is not zero when R⁴ is hydroxy or alkoxy; and

R⁵ is selected from hydrogen, hydroxy, and cycloalkyl.

In another aspect, the present invention provides a composition for treating a patient in need of anti-angiogenesis therapy comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier.

Yet another aspect of the present invention provides a method for treating a patient in need of anti-angiogenesis therapy comprising administering to the patient a therapeutically effective amount of a compound of formula (I).

Still yet another aspect of the present invention provides a composition for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention, macular degeneration, and diabetic retinopathy comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier.

In yet another aspect, the present invention provides a method of isolating a receptor from an endothelial cell comprising binding a compound of formula (I) to the

receptor to form a peptide receptor complex, isolating the peptide receptor complex, and purifying the receptor.

Detailed Description of the Invention

5 Definition of Terms

As used herein, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise.

As used in the present specification the following terms have the meanings indicated:

10 The term "N-acetylamino," as used herein, refers to -NHC(O)CH_3 .

The term "acyl," as used herein, refers to an alkyl group attached to the parent molecular moiety through a carbonyl group.

The term "alkoxy," as used herein, refers to an alkyl group attached to the parent molecular moiety through an oxygen atom.

15 The term "alkyl," as used herein, refers to a monovalent group derived from a straight or branched chain saturated hydrocarbon by the removal of a hydrogen atom. Preferred alkyl groups for the invention are $\text{C}_1\text{-C}_6$ alkyl groups having from one to six carbon atoms. Alkyl groups of one to three carbon atoms ($\text{C}_1\text{-C}_3$ alkyl) are more preferred for the invention.

20 The term "amino," as used herein, refers to -NH_2 .

The term "aryl," as used herein, refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings and is exemplified by phenyl, naphthyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, fluorenyl, indanyl, indenyl, and the like.

The term "carbonyl," as used herein, refers to -C(O)- .

25 The term "carboxy," as used herein, refers to $\text{-CO}_2\text{H}$.

The term "cycloalkenyl," as used herein, refers to a non-aromatic cyclic or bicyclic ring system having three to ten carbon atoms and one to three rings, wherein each five-membered ring has one double bond, each six-membered ring has one or two double bonds, each seven- and eight-membered ring has one to three double bonds, and each 30 nine-to ten-membered ring has one to four double bonds. Examples of cycloalkenyl groups include cyclohexenyl, octahydronaphthalenyl, norbornylenyl, and the like. The cycloalkenyl groups of the present invention can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkoxy, alkyl, carboxy, halo, and hydroxy.

35 The term "cycloalkyl," as used herein, refers to a saturated monocyclic, bicyclic, or tricyclic hydrocarbon ring system having three to twelve carbon atoms. Examples of

cycloalkyl groups include cyclopropyl, cyclopentyl, bicyclo[3.1.1]heptyl, adamantyl, and the like. The cycloalkyl groups of the present invention can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkoxy, alkyl, carboxy, halo, and hydroxy.

5 The term "halo," as used herein, refers to F, Cl, Br, or I.

 The term "heterocycle," as used herein, refers to a five-, six-, or seven-membered ring containing one, two, or three heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The five-membered ring has zero to two double bonds and the six- and seven-membered rings have zero to three double bonds.

10 The term "heterocycle" also includes bicyclic groups in which the heterocycle ring is fused to an aryl group. The heterocycle groups of the present invention can be attached through a carbon atom or a nitrogen atom in the group. Examples of heterocycles include, but are not limited to, furyl, thienyl, pyrrolyl, pyrrolidinyl, oxazolyl, thiazolyl, imidazolyl, imidazoliny, pyrazolyl, isoxazolyl, isothiazolyl, piperidinyl, morpholinyl,
15 thiomorpholinyl, piperazinyl, pyridinyl, indolyl, indolinyl, benzothienyl, and the like. The heterocycle groups of the present invention can be optionally substituted with one, two, three, or four substituents independently selected from the group consisting of alkoxy, alkyl, carboxy, halo, and hydroxy.

 The term "hydroxy," as used herein, refers to -OH.

20 The term "nicotinyl," as used herein, refers to the acyl group derived from nicotinic acid, i.e. pyridine-3-carboxylic acid.

 The term "nitrogen protecting group" or "N-protecting group," as used herein, refers to an easily removable group which is known in the art to protect an amino group against undesirable reaction during synthetic procedures and to be selectively removable.

25 The use of nitrogen protecting groups is well known in the art for protecting groups against undesirable reactions during a synthetic procedure and many such protecting groups are known (see, for example, T.H. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2nd edition, John Wiley & Sons, New York (1991). Examples of N-protecting groups include, are not limited to, acyl groups including acetyl, trifluoroacetyl,
30 acylisothiocyanate, aminocaproyl, benzoyl and the like, and acyloxy groups, including *t*-butoxycarbonyl (Boc) and carbobenzyloxy (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), and the like.

 The term "pharmaceutically acceptable ester," as used herein, refers to esters which hydrolyze *in vivo* and include those that break down readily in the human body to
35 leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly

alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than six carbon atoms. Examples of particular esters include formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.

5 The term "pharmaceutically acceptable prodrugs," as used herein, refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term
10 "prodrug" refers to compounds that are rapidly transformed *in vivo* to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press,
15 1987, both of which are incorporated herein by reference.

The term "pharmaceutically acceptable salt," as used herein, represents salts or zwitterionic forms of the compounds of the present invention which are water or oil-soluble or dispersible, which are suitable for treatment of diseases without undue toxicity, irritation, and allergic response; which are commensurate with a reasonable benefit/risk
20 ratio, and which are effective for their intended use. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate,
25 formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate,
30 and undecanoate. Also, amino groups in the compounds of the present invention can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic
35 acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.

Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of pharmaceutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-phenamine, and N,N'-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.

The term "pharmaceutically acceptable solvate," as used herein, refers to an aggregate that comprises one or more molecules of the solute, such as a compound of formula (I), with one or more molecules of solvent.

The term "receptor," as used herein, refers to chemical groups or molecules on the cell surface or in the cell interior that have an affinity for a specific chemical group or molecule. Isolation of receptors relevant to the antiangiogenic activity of the peptide of the invention can provide useful diagnostic tools.

The term "shikimyl," as used herein, refers to the acyl residue derived from shikimic acid or [3R-(3 α ,4 α ,5 β)-3,4,5-trihydroxy]-1-cyclohexene-1-carboxylic acid. A "dihydroshikimyl" group denotes the fully saturated analog of shikimic acid.

The term "succinyl," as used herein, refers to the acyl residue derived from succinic acid or (1,4-dioxobutyl)-1-carboxylic acid.

Unless indicated otherwise by a "D-" prefix, *e.g.* D-Ala or N-Me-D-Ile, the stereochemistry of the α -carbon of the amino acids and aminoacyl residues in peptides described in this specification and the appended claims is the natural or "L" configuration. The Cahn-Ingold-Prelog "R" and "S" designations are used to specify the stereochemistry of chiral centers in certain acyl substituents at the N-terminus of the peptides of this invention. The designation "R,S" is meant to indicate a racemic mixture of the two enantiomeric forms. This nomenclature follows that described in R.S. Cahn, *et al.*, *Angew. Chem. Int. Ed. Engl.*, **5**, 385-415 (1966).

All peptide sequences are written according to the generally accepted convention whereby the α -N-terminal amino acid residue is on the left and the α -C-terminal is on the right. As used herein, the term " α -N-terminal" refers to the free α -amino group of an

amino acid in a peptide, and the term “ α -C-terminal” refers to the free α -carboxylic acid terminus of an amino acid in a peptide.

- For the most part, the names on naturally occurring and non-naturally occurring aminoacyl residues used herein follow the naming conventions suggested by the IUPAC Commission on the Nomenclature of Organic Chemistry and the IUPAC-IUB Commission on Biochemical Nomenclature as set out in "Nomenclature of α -Amino Acids (Recommendations, 1974) " Biochemistry, 14(2), (1975). To the extent that the names and abbreviations of amino acids and aminoacyl residues employed in this specification and appended claims differ from those suggestions, they will be made clear to the reader. Some abbreviations useful in describing the invention are defined below in the following Table 1.

Table 1

Abbreviation	Definition
N-Ac-Sar	N-acetylsarcosyl
Ala	alanyl
β -Ala	β -alanyl
AlaNH ₂	alanylamine
AlaNH-ethyl	alanyl ethylamine
alloIle	alloisoleucyl
alloThr	allothreonyl
AllylGly	allylglycyl
2-Abu	2-aminobutyryl
(1R,4S)-AmCycCO	(1R,4S)-1-aminocyclopent-2-ene-4-carbonyl
Aib	2-aminoisobutyryl
AiPheAla	3-(4-amino-N-isopropylphenyl)alanyl
AimPheAla	[(4-amino(N-isopropyl)methyl)phenyl]alanyl
4-AmPheAla	3-(4-aminophenyl)alanyl
Arg	arginyl
Arg(diethyl)	arginyl(N ^G N ^{G'} diethyl)

Asn	asparaginy
Asp	aspartyl
AzaGlyNH ₂	azaglycylamide
BiPheAla	3-(4,4'-biphenyl)alanyl
5-BrThiAla	3-(5-bromothien2-yl)alanyl
Gly(<i>t</i> -Bu)	<i>t</i> -butylglycyl
CamdPheAla	3-(4-carboxyamidophenyl)alanyl
3-ClPheAla	3-(3-chlorophenyl)alanyl
4-ClPheAla	3-(4-chlorophenyl)alanyl
Cit	citrullyl
3-CNPheAla	3-(3-cyanophenyl)alanyl
Cha	cyclohexylalanyl
Cha(Isp)	3-(cyclohexyl)alanyl(N-isopropyl)
Chg	cyclohexylglycyl
Cys	cysteinyl
Cys(<i>t</i> -Bu)	cysteinyl(S- <i>t</i> -butyl)
Cys(Et)	cysteinyl(S-ethyl)
Cys(Me)	cysteinyl(S-methyl)
deLeu	dehydroleucyl
2,4-Diabu	2,4-diaminobutyryl
2,3-Diapr	2,3-diaminopropionyl
3,4-diFPheAla	3-(3,4-difluorophenyl)alanyl
3,4-diOMePheAla	3-(3,4-dimethoxyphenyl)alanyl
Gly(Et)	N-ethylglycyl
Fmoc	9-fluorenylmethyloxycarbonyl
3-FPheAla	3-(3-fluorophenyl)alanyl
4-FPheAla	3-(4-fluorophenyl)alanyl
Gln	glutaminy
Gln(Trt)	glutaminy(trityl)


Glu	glutamyl
Gly	glycyl
GlyNH ₂	glycylamide
GlyNH-ethyl	glycyl ethylamide
Gly(pipad)	glycyl[4-piperidynyl(N-amidino)]
GuaAla	3-(guanidino)alanyl
4-GuaPheAla	3-(4-guanidinophenyl)alanyl
His	histidyl
His(Trt)	histidyl(trityl)
HAla	homoalanyl
HArg	homoarginyl
HIle	homoisoleucyl
HLeu	homoleucyl
HPheAla	homophenylalanyl
HPro	homopropyl
HSer	homoseryl
HSer(<i>t</i> -Bu)	homoseryl(O- <i>t</i> -butyl)
4-OHMePheAla	3-(4-hydroxymethylphenyl)alanyl
OHPro	hydroxypropyl
Ile	isoleucyl
Leu	leucyl
Lys	lysyl
Lys(Ac)	lysyl(N-epsilon-acetyl)
Lys(Isp)	lysyl(N-epsilon-isopropyl)
Lys(Nic)	lysyl(N-epsilon-nicotinyl)
Met	methionyl
Met(O ₂)	methionyl(sulfone)
Met(O)	methionyl(sulfoxide)
N-MeAla	N-methylalanyl

Sar	sarcosyl
SarNH ₂	sarcosylamide
Ser	seryl
SerNH ₂	serylamide
Ser(Bzl)	seryl(O-benzyl)
StyAla	styrylalanyl
Tic	1,2,3,4-tetrahydroisoquinoline-3-carbonyl
3-ThzAla	3-(3-thiazolyl)alanyl
2-ThiAla	3-(thien-2-yl)alanyl
Thr	threonyl
Thr(Bzl)	threonyl(O-benzyl)
Thr(<i>t</i> -Bu)	threonyl(O- <i>t</i> -butyl)
3-CF ₃ PheAla	3-(3-trifluoromethylphenyl)alanyl
3,4,5-TriFPheAla	3-(3,4,5-trifluorophenyl)alanyl
Trp	tryptyl
Trp(Boc)	tryptyl(N- <i>t</i> -butoxycarbonyl)
Tyr	tyrosyl
Tyr(<i>t</i> -Bu)	tyrosyl(O- <i>t</i> -butyl)
Tyr(Bzl)	tyrosyl(O-benzyl)
Tyr(Et)	tyrosyl(O-ethyl)
Val	valyl

When not found in the table above, nomenclature and abbreviations may be further clarified by reference to the Calbiochem-Novabiochem Corp. *1999 Catalog and Peptide Synthesis Handbook* or the Chem-Impex International, Inc. *Tools for Peptide & Solid*

5 *Phase Synthesis 1998-1999 Catalogue.*

In one aspect, the present invention relates to compounds of the structure



wherein Xaa₂, Xaa₃, Xaa₄, Xaa₅, Xaa₆, Xaa₇, Xaa₈, Xaa₉, and Xaa₁₀ represent the residues
 10 of a peptide having nine amino acids. The N-terminus of the nonapeptide represented can

be modified by an amino acyl group represented by Xaa₁. The group Xaa₁ represents a group suitable for modifying the C-terminus of the compound.

Suitable groups for Xaa₁ are hydrogen, an acyl group of the formula R¹-(CH₂)_n-C(O)-; wherein n is an integer from 0 to 8 and R¹ is selected from the group consisting of N-acetylamino, alkoxy, alkyl, aryl, carboxy, cycloalkenyl, cycloalkyl, heterocycle, and hydroxy; and an acyl group of the formula R²-CH₂CH₂-O-(CH₂CH₂O)_p-CH₂-C(O)-, wherein R² is selected from the group consisting of hydrogen, N-acetylamino, and alkyl, and p is an integer from 1 to 8. Preferred Xaa₁ groups for modifying the N-terminus of the compounds in the scope of the invention are acetyl and 6-methylnicotinyl.

Xaa₂ is an amino acyl residue selected from the group consisting of alanyl, β-alanyl, asparaginy, citrully, N-ethylglycyl, glutaminy, glutamyl, methionyl, N-methylalanyl, N-methylprolyl, prolyl, pyro-glutamyl, sarcosyl, seryl, threonyl, H₃C-C(O)-HN-(CH₂)_q-C(O)-, wherein q is 1 to 8, and H₃C-C(O)-HN-CH₂CH₂-O-(CH₂CH₂O)_r-CH₂-C(O)-, wherein r is 1 to 8; provided that when Xaa₂ is N-methylprolyl, H₃C-C(O)-HN-(CH₂)_q-C(O)-, or H₃C-C(O)-HN-CH₂CH₂-O-(CH₂CH₂O)_r-CH₂-C(O)-, Xaa₁ is absent. Preferably, Xaa₂ is sarcosyl.

Xaa₃ is an amino acyl residue selected from the group consisting of alanyl, asparaginy, aspartyl, glutaminy, glutamyl, glycyl, leucyl, methionyl, phenylalanyl, prolyl, and seryl. The preferred amino acid for Xaa₃ is glycyl.

Xaa₄ is an amino acyl residue selected from the group consisting of alloisoleucyl, allylglycyl, 2-aminobutyryl, (1R,4S)-1-aminocyclopent-2-ene-4-carbonyl, aspartyl, 3-(5-bromothien-2-yl)alanyl, 3-(3-chlorophenyl)alanyl, 3-(4-chlorophenyl)alanyl, 3-(3-cyanophenyl)alanyl, cysteinyl(S-ethyl), cysteinyl(S-methyl), 2,4-diaminobutanoyl, 2,3-diaminopropionyl, 3-(3,4-dimethoxyphenyl)alanyl, 3-(3-fluorophenyl)alanyl, 3-(4-fluorophenyl)alanyl, histidyl, homophenylalanyl, homoseryl, lysyl(N-epsilon-acetyl), methionyl(sulfone), methionyl(sulfoxide), 3-(4-methylphenyl)alanyl, 3-(naphth-1-yl)alanyl, 3-(naphth-2-yl)alanyl, ornithyl, phenylglycyl, prolyl, 3-(3-pyridyl)alanyl, 3-(thiazolyl)alanyl, 3-(thien-2-yl)alanyl, D-3-(thien-2-yl)alanyl, seryl(O-benzyl), styrylalanyl, 1,2,3,4-tetrahydroisoquinoline-3-carbonyl, tryptyl, tyrosyl, and D-valyl. Preferred amino acyl residues for the Xaa₄ position include alloisoleucyl, allylglycyl, 2-aminobutyryl, (1R,4S)-1-aminocyclopent-2-ene-4-carbonyl, 3-(5-bromothien-2-yl)alanyl, 3-(3-chlorophenyl)alanyl, 3-(4-chlorophenyl)alanyl, 3-(3-cyanophenyl)alanyl, cysteinyl(S-ethyl), cysteinyl(S-methyl), 2,4-diaminobutanoyl, 2,3-diaminopropionyl, 3-(3,4-dimethoxyphenyl)alanyl, 3-(3-fluorophenyl)alanyl, 3-(4-fluorophenylalanyl), histidyl, homophenylalanyl, homoseryl, lysyl(N-epsilon-acetyl), methionyl(sulfone), methionyl(sulfoxide), 3-(4-methylphenyl)alanyl, 3-(naphth-1-yl)alanyl, 3-(naphth-2-

yl)alanyl, ornithyl, phenylglycyl, prolyl, 3-(3-pyridyl)alanyl, seryl(O-benzyl), styrylalanyl, 1,2,3,4-tetrahydroisoquinoline-3-carbonyl, 3-(thiazolyl)alanyl, 3-(thien-2-yl)alanyl, D-3-(thien-2-yl)alanyl, tryptyl, tyrosyl, and D-valyl.

Xaa₅ is an amino acyl residue selected from the group consisting of D-alanyl, 5
alloisoleucyl, D-alloisoleucyl, D-allothreonyl, D-allylglycyl, D-2-aminobutyryl, D-3-(4-aminophenyl)alanyl, D-asparaginy, D-aspartyl, D-3-(4,4'-biphenyl)alanyl, D-*t*-butylglycyl, D-3-(4-chlorophenyl)alanyl, D-3-(3-cyanophenyl)alanyl, D-citrullyl, D-cyclohexylalanyl, D-cyclohexylglycyl, D-cysteinyl, D-cysteinyl(S-*t*-butyl), dehydroleucyl, D-3-(3,4-difluorophenyl)alanyl, D-3-(3,4-dimethoxyphenyl)alanyl, D-glutaminy, D-10
glutamyl, glycyl, D-histidyl, D-homoisoleucyl, D-homophenylalanyl, D-homoseryl, isoleucyl, D-isoleucyl, D-leucyl, D-lysyl, D-lysyl(N-epsilon-nicotinyl), D-methionyl, D-3-(4-methylphenyl)alanyl, D-3-(naphth-1-yl)alanyl, D-3-(naphth-2-yl)alanyl, D-neopentylglycyl, D-3-(4-nitrophenyl)alanyl, D-norleucyl, D-norvalyl, D-ornithyl, D-penicillaminy, D-penicillaminy(S-acetamidomethyl), D-penicillaminy(S-benzyl), D-15
penicillaminy(S-methyl), D-phenylalanyl, prolyl, D-prolyl, D-3-(3-pyridyl)alanyl, D-seryl, D-seryl(O-benzyl), D-3-(thien-2-yl)alanyl, D-3-(3-trifluoromethylphenyl)alanyl, D-3-(3,4,5-trifluorophenyl)alanyl, D-threonyl, D-threonyl(O-benzyl), D-tryptyl, D-tyrosyl(O-benzyl), D-tyrosyl(O-ethyl), D-tyrosyl, and D-valyl. Preferred Xaa₅ amino acyl residues include isoleucyl, D-isoleucyl, and D-leucyl.

20 Xaa₆ is an amino acyl selected from the group consisting of alanyl, allothreonyl, D-allothreonyl, allylglycyl, asparaginy, cysteinyl, glutaminy, glycyl, histidyl, homoseryl, D-homoseryl, 3-(4-hydroxymethylphenyl)alanyl, isoleucyl, lysyl(N-epsilon-acetyl), methionyl, 3-(naphth-1-yl)alanyl, 3-(naphth-2-yl)alanyl, norvalyl, octylglycyl, ornithyl, penicillaminy, prolyl, 3-(3-pyridyl)alanyl, seryl, D-seryl, threonyl, D-threonyl, tryptyl, 25
and tyrosyl. Preferred amino acyl residues for the Xaa₆ position include seryl and threonyl.


Xaa₇ is an amino acyl residue selected from the group consisting of alanyl, allylglycyl, 2-aminobutyryl, arginy, asparaginy, aspartyl, 3-(4-carboxyamidophenyl)alanyl, citrullyl, cyclohexylalanyl, cysteinyl, glutaminy, D-30
glutaminy, glutamyl, glycyl, histidyl, homoalanyl, homoleucyl, homoseryl, D-homoseryl, isoleucyl, leucyl, D-leucyl, lysyl(N-epsilon-acetyl), lysyl(N-epsilon-isopropyl), methionyl(sulfone), methionyl(sulfoxide), methionyl, 3-(naphth-1-yl)alanyl, D-3-(naphth-1-yl)alanyl, 3-(naphth-2-yl)alanyl, D-3-(naphth-2-yl)alanyl, norleucyl, norvalyl, D-norvalyl, octylglycyl, penicillaminy, phenylalanyl, propargylglycyl, 3-(3-pyridyl)alanyl, 35
seryl, D-seryl, threonyl, tryptyl, tyrosyl, and valyl. Preferred Xaa₇ amino acyl residues include glutaminy, norvalyl, and seryl.

Xaa₈ is an amino acyl residue selected from the group consisting of alanyl, alloisoleucyl, D-alloisoleucyl, allylglycyl, aspartyl, *t*-butylglycyl, citrullyl, cyclohexylglycyl, cysteinyl, glutamyl, glycyl, homoseryl, isoleucyl, D-isoleucyl, leucyl, lysyl(N-epsilon-acetyl), methionyl, 3-(naphth-1-yl)alanyl, 3-(naphth-2-yl)alanyl,
 5 norvalyl, penicillaminy, phenylalanyl, prolyl, seryl, tryptyl, tyrosyl, and valyl. The preferred Xaa₈ amino acyl residue is isoleucyl.

Xaa₉ is an amino acyl residue selected from the group consisting of [(4-amino(N-isopropyl)methyl)phenyl]alanyl, 3-(4-amino-N-isopropylphenyl)alanyl, arginyl, arginyl(N^GN^Gdiethyl), citrullyl, 3-(cyclohexyl)alanyl(4-N-isopropyl), glycyl[4-piperidiny(N-amidino)], (3-guanidino)alanyl, 3-(4-guanidinophenyl)alanyl, histidyl,
 10 homoarginyl, lysyl, lysyl(N-epsilon-isopropyl), lysyl(N-epsilon-nicotinyl), norarginyl, ornithyl(N-delta-isopropyl), ornithyl(N-delta-nicotinyl), ornithyl[N-delta-(2-imidazoliny)], [4-piperidiny(N-amidino)]alanyl, and [3-pyrrolidiny(2-N-amidino)]alanyl. The preferred Xaa₉ amino acyl residue is arginyl.

Xaa₁₀ is an amino acyl residue selected from the group consisting of D-alanyl, 2-aminobutyryl, 2-aminoisobutyryl, *t*-butylglycyl, homoprolyl, hydroxypropyl, isoleucyl, leucyl, phenylalanyl, prolyl, D-prolyl, seryl, 1,2,3,4-tetrahydroisoquinoline-3-carbonyl, threonyl, and valyl. The preferred Xaa₁₀ amino acyl residue is prolyl.

Xaa₁₁ is a hydroxyl group or an amino acid amide selected from the group
 20 consisting of D-alanylamide, D-alanylethylamide, azaglycylamide, glycylamide, glycylethylamide, sarcosylamide, serylamide, and D-serylamide; or Xaa₁₁ is a group represented by the formula



or a group represented by the formula -NH-R^5 , wherein *s* is an integer selected from 0 to
 25 8; R³ is selected from hydrogen, alkyl, and a 5- to 6-membered cycloalkyl ring; R⁴ is selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, cycloalkenyl, cycloalkyl, heterocycle, and hydroxy; provided that *s* is not zero when R⁴ is hydroxy or alkoxy; and R⁵ is selected from hydrogen, hydroxy, and cycloalkyl. The preferred Xaa₁₁ residues include D-alanylamide and NH-ethyl.

30

Compositions

The compounds of the invention, including but not limited to those specified in the examples, possess anti-angiogenic activity. As angiogenesis inhibitors, such compounds are useful in the treatment of both primary and metastatic solid tumors, including
 35 carcinomas of breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach,

pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract (including kidney, bladder and urothelium), female genital tract, (including cervix, uterus, and ovaries as well as choriocarcinoma and gestational trophoblastic disease), male genital tract (including prostate, seminal vesicles, testes and and germ cell tumors), endocrine glands (including the thyroid, adrenal, and pituitary glands), and skin, as well as hemangiomas, melanomas, sarcomas (including those arising from bone and soft tissues as well as Kaposi's sarcoma) and tumors of the brain, nerves, eyes, and meninges (including astrocytomas, gliomas, glioblastomas, retinoblastomas, neuromas, neuroblastomas, Schwannomas, and meningiomas). Such compounds may also be useful in treating solid tumors arising from hematopoietic malignancies such as leukemias (i.e. chloromas, plasmacytomas and the plaques and tumors of mycosis fungoides and cutaneous T-cell lymphoma/leukemia) as well as in the treatment of lymphomas (both Hodgkin's and non-Hodgkin's lymphomas). In addition, these compounds may be useful in the prevention of metastases from the tumors described above either when used alone or in combination with radiotherapy and/or other chemotherapeutic agents.

Further uses include the treatment and prophylaxis of autoimmune diseases such as rheumatoid, immune and degenerative arthritis; various ocular diseases such as diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, retrolental fibroplasia, neovascular glaucoma, rubeosis, retinal neovascularization due to macular degeneration, hypoxia, angiogenesis in the eye associated with infection or surgical intervention, and other abnormal neovascularization conditions of the eye; skin diseases such as psoriasis; blood vessel diseases such as hemangiomas, and capillary proliferation within atherosclerotic plaques; Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; and wound granulation. Other uses include the treatment of diseases characterized by excessive or abnormal stimulation of endothelial cells, including but not limited to intestinal adhesions, Crohn's disease, atherosclerosis, scleroderma, and hypertrophic scars, i.e. keloids. Another use is as a birth control agent, by inhibiting ovulation and establishment of the placenta. The compounds of the invention are also useful in the treatment of diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (*Rochelie minalia quintosa*) and ulcers (*Helicobacter pylori*). The compounds of the invention are also useful to reduce bleeding by administration prior to surgery, especially for the treatment of resectable tumors.

The compounds of the invention may be used in combination with other compositions and procedures for the treatment of diseases. For example, a tumor may be treated conventionally with surgery, radiation or chemotherapy combined with a peptide

of the present invention and then a peptide of the present invention may be subsequently administered to the patient to extend the dormancy of micrometastases and to stabilize and inhibit the growth of any residual primary tumor. Additionally, the compounds of the invention may be combined with pharmaceutically acceptable excipients, and optionally
5 sustained-release matrices, such as biodegradable polymers, to form therapeutic compositions.

A sustained-release matrix, as used herein, is a matrix made of materials, usually polymers, which are degradable by enzymatic or acid-base hydrolysis or by dissolution. Once inserted into the body, the matrix is acted upon by enzymes and body fluids. A
10 sustained-release matrix desirably is chosen from biocompatible materials such as liposomes, polylactides (polylactic acid), polyglycolide (polymer of glycolic acid), polylactide co-glycolide (copolymers of lactic acid and glycolic acid) polyanhydrides, poly(ortho)esters, polypeptides, hyaluronic acid, collagen, chondroitin sulfate, carboxylic acids, fatty acids, phospholipids, polysaccharides, nucleic acids, polyamino acids, amino
15 acids such as phenylalanine, tyrosine, isoleucine, polynucleotides, polyvinyl propylene, polyvinylpyrrolidone and silicone. A preferred biodegradable matrix is a matrix of one of either polylactide, polyglycolide, or polylactide co-glycolide (co-polymers of lactic acid and glycolic acid).

When used in the above or other treatments, a therapeutically effective amount of
20 one of the compounds of the present invention may be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt form. By a "therapeutically effective amount" of the compound of the invention is meant a sufficient amount of the compound to treat an angiogenic disease, (for example, to limit tumor growth or to slow or block tumor metastasis) at a reasonable benefit/risk ratio applicable to any medical treatment. It
25 will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific
30 composition employed, the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the
35 compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

Alternatively, a compound of the present invention may be administered as pharmaceutical compositions containing the compound of interest in combination with one or more pharmaceutically acceptable excipients. A pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The compositions may be administered parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, drops or transdermal patch), rectally, or buccally. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Pharmaceutical compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity may be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like.

Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption, such as aluminum monostearate and gelatin.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters), poly(anhydrides), and (poly)glycols, such as PEG. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations may be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Topical administration includes administration to the skin or mucosa, including surfaces of the lung and eye. Compositions for topical administration, including those for inhalation, may be prepared as a dry powder which may be pressurized or non-pressurized. In non-pressurized powder compositions, the active ingredient in finely divided form may be used in admixture with a larger-sized pharmaceutically acceptable inert carrier comprising particles having a size, for example, of up to 100 micrometers in diameter. Suitable inert carriers include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.

Alternatively, the composition may be pressurized and contain a compressed gas, such as nitrogen or a liquified gas propellant. The liquified propellant medium and indeed the total composition is preferably such that the active ingredient does not dissolve therein to any substantial extent. The pressurized composition may also contain a surface active agent, such as a liquid or solid non-ionic surface active agent or may be a solid anionic surface active agent. It is preferred to use the solid anionic surface active agent in the form of a sodium salt.

A further form of topical administration is to the eye. A compound of the invention is delivered in a pharmaceutically acceptable ophthalmic vehicle, such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye, as for example the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/ciliary, lens, choroid/retina and sclera. The pharmaceutically acceptable ophthalmic vehicle may, for example, be an ointment, vegetable oil or an encapsulating material. Alternatively, the compounds of the invention may be injected directly into the vitreous and aqueous humour.

Compositions for rectal or vaginal administration are preferably suppositories which may be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Compounds of the present invention may also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present

invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 *et seq.*

5 While the compounds of the invention can be administered as the sole active pharmaceutical agent, they may also be used in combination with one or more agents which are conventionally administered to patients for treating angiogenic diseases. For example, the compounds of the invention are effective over the short term to make tumors more sensitive to traditional cytotoxic therapies such as chemicals and radiation. The
10 compounds of the invention also enhance the effectiveness of existing cytotoxic adjuvant anti-cancer therapies. The compounds of the invention may also be combined with other antiangiogenic agents to enhance their effectiveness, or combined with other antiangiogenic agents and administered together with other cytotoxic agents. In particular, when used in the treatment of solid tumors, compounds of the invention may be
15 administered with IL-12, retinoids, interferons, angiostatin, endostatin, thalidomide, thrombospondin-1, thrombospondin-2, captopryl, angioinhibins, TNP-470, pentosan polysulfate, platelet factor 4, LM-609, SU-5416, CM-101, Tecogalan, plasminogen-K-5, vasostatin, vitaxin, vasculostatin, squalamine, marimastat or other MMP inhibitors, anti-neoplastic agents such as alpha interferon, COMP (cyclophosphamide, vincristine,
20 methotrexate and prednisone), etoposide, mBACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone), PRO-MACE/MOPP (prednisone, methotrexate (w/leucovin rescue), doxorubicin, cyclophosphamide, cisplatin, taxol, etoposide/mechlorethamine, vincristine, prednisone and procarbazine), vincristine, vinblastine, and the like as well as with radiation.

25 Total daily dose of the compositions of the invention to be administered to a human or other mammal host in single or divided doses may be in amounts, for example, from 0.0001 to 300 mg/kg body weight daily and more usually 1 to 300 mg/kg body weight.

30 It will be understood that agents which can be combined with the compound of the present invention for the inhibition, treatment or prophylaxis of angiogenic diseases are not limited to those listed above, but include in principle any agents useful for the treatment or prophylaxis of angiogenic diseases.

35 The peptides of the invention may be used for the development of affinity columns for isolation of receptors relevant to the antiangiogenic activity of the peptide of the invention, e.g. TSP-1 receptor, in, for example, cultured endothelial cells. Isolation and purification of the receptor may be followed by amino acid sequencing to identify and

isolate polynucleotides which encode the receptor. Recombinant expression of this receptor would allow greater amounts of receptor to be produced, e.g. to produce a sufficient quantity for use in high throughput screening assays to identify other angiogenesis inhibitors.

5

Determination of Biological Activity

In Vitro Assay for Angiogenic Activity

The human microvascular endothelial (HMVEC) migration assay was run according to the procedure of S. S. Tolsma, O. V. Volpert, D. J. Good, W. F. Frazier, P. J. Polverini and N. Bouck, J. Cell Biol. 122, 497-511 (1993).

The HMVEC migration assay was carried out using Human Microvascular Endothelial Cells-Dermal (single donor) and Human Microvascular Endothelial Cells, (neonatal). The BCE or HMVEC cells were starved overnight in DME containing 0.1% bovine serum albumin (BSA). Cells were then harvested with trypsin and resuspended in DME with 0.1% BSA at a concentration of 1.5×10^6 cells per mL. Cells were added to the bottom of a 48 well modified Boyden chamber (Nucleopore Corporation, Cabin John, MD). The chamber was assembled and inverted, and cells were allowed to attach for 2 hours at 37 °C to polycarbonate chemotaxis membranes (5mM pore size) that had been soaked in 0.1% gelatin overnight and dried. The chamber was then reinverted, and test substances (total volume of 50 µL), including activators, 15 ng/mL bFGF/VEGF, were added to the wells of the upper chamber. The apparatus was incubated for 4 hours at 37 °C. Membranes were recovered, fixed and stained (Diff Quick, Fisher Scientific) and the number of cells that had migrated to the upper chamber per 3 high power fields counted. Background migration to DME + 0.1 BSA was subtracted and the data reported as the number of cells migrated per 10 high power fields (400X) or, when results from multiple experiments were combined, as the percent inhibition of migration compared to a positive control.

Representative compounds described in Examples 1 to 50 inhibited human endothelial cell migration in the above assay by at least 50% inhibition when tested at concentrations of 1 nM. Preferred compounds inhibited human endothelial cell migration by at least 70% when tested at concentrations of 1 nM, and more preferred compounds inhibited human endothelial cell migration by at least 80% at concentrations of 1 nM.

Synthesis of the Peptides

The polypeptides of the present invention may be synthesized by many techniques that are known to those skilled in the art. For solid phase peptide synthesis, a summary of

the many techniques may be found in J.M. Stewart and J.D. Young, Solid Phase Peptide Synthesis, W.H. Freeman Co. (San Francisco), 1963 and J. Meienhofer, Hormonal Proteins and Peptides, vol. 2, p. 46, Academic Press (New York), 1973. For classical solution synthesis see G. Schroder and K. Lupke, The Peptides, vol. 1, Academic Press (New York), 1965.

Reagents, resins, amino acids, and amino acid derivatives are commercially available and can be purchased from Chem-Impex International, Inc. (Wood Dale, IL, U.S.A.) or Calbiochem-Novabiochem Corp. (San Diego, CA, U.S.A.) unless otherwise noted herein.

In general, these methods comprise the sequential addition of one or more amino acids or suitably protected amino acids to a growing peptide chain. Normally, either the amino or carboxy group of the first amino acid is protected by a suitable nitrogen protecting group. The protected or derivatized amino acid can then be either attached to an inert solid support or utilized in solution by adding the next amino acid in the sequence having the complimentary (amino or carboxy) group suitably protected, under conditions suitable for forming the amide linkage. The protecting group is then removed from this newly added amino acid residue and the next amino acid (suitably protected) is then added, and so forth. After all the desired amino acids have been linked in the proper sequence, any remaining protecting groups (and any solid support) are removed sequentially or concurrently to afford the final polypeptide. By simple modification of this general procedure, it is possible to add more than one amino acid at a time to a growing chain, for example, by coupling (under conditions which do not racemize chiral centers) a protected tripeptide with a properly protected dipeptide to form, after deprotection, a pentapeptide.

A particularly preferred method of preparing compounds of the present invention involves solid phase peptide synthesis.

In this particularly preferred method the α -amino functionality is protected by an acid or base sensitive group. Such protecting groups should have the properties of being stable to the conditions of peptide linkage formation, while being readily removable without destruction of the growing peptide chain or racemization of any of the chiral centers contained therein. Suitable protecting groups are 9-fluorenylmethoxycarbonyl (Fmoc), *t*-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), biphenylisopropyl-oxy carbonyl, *t*-amyloxycarbonyl, isobornyloxycarbonyl, (α,α)-dimethyl-3,5-dimethoxybenzyloxycarbonyl, *O*-nitrophenylsulfenyl, 2-cyano-*t*-butoxycarbonyl, and the like. The 9-fluorenylmethoxycarbonyl (Fmoc) protecting group is preferred.

Particularly preferred side chain protecting groups are: for arginine and lysine: acetyl (Ac), adamantyloxycarbonyl, benzyloxycarbonyl (Cbz), *t*-butoxycarbonyl (Boc), 4-methoxybenzenesulfonyl, N^G-4-methoxy-2,3,6-trimethylbenzenesulfonyl (Mtr), 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc), and *p*-toluenesulfonyl; for asparagine: trityl (Trt);
5 for aspartyl: *t*-butyl (*t*-Bu); for glutamyl: *t*-butyl (*t*-Bu); for glutaminyl: trityl (Trt); for histidine: trityl (Trt), benzyl, benzyloxycarbonyl (Cbz), *p*-toluenesulfonyl, and 2,4-dinitrophenyl; for penicillamine: methyl; for serine: *t*-butyl (*t*-Bu); for tryptophan: formyl and *t*-butoxycarbonyl (Boc); and for tyrosine: acetyl (Ac), benzyl, *O*-bromobenzyloxycarbonyl, *t*-butyl (*t*-Bu), cyclohexyl, cyclopentyl, 2,6-dichlorobenzyl, and
10 isopropyl.

In the solid phase peptide synthesis method, the C-terminal amino acid is attached to a suitable solid support or resin. Suitable solid supports useful for the above synthesis are those materials which are inert to the reagents and reaction conditions of the stepwise condensation-deprotection reactions, as well as being insoluble in the media used. The
15 preferred solid support is Seiber ethylamide, which is commercially available from Novabiochem.

The C-terminal amino acid is coupled to the resin by means of a coupling mediated by N,N'-dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide (DIC), *O*-benzotriazol-1-yl-N,N,N',N'-tetramethyluroniumhexafluorophosphate (HBTU), or [*O*-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate] (HATU), with or
20 without 4-dimethylaminopyridine (DMAP), 1-hydroxybenzotriazole (HOBT), benzotriazol-1-yloxy-tris(dimethylamino)phosphoniumhexafluorophosphate (BOP), or bis(2-oxo-3-oxazolidinyl)phosphine chloride (BOPCl), for about 1 to about 24 hours at a temperature between 10 °C and 50 °C in a solvent such as dichloromethane or DMF. The
25 Fmoc group is cleaved with a secondary amine, preferably piperidine, prior to coupling with the C-terminal amino acid as described above. The preferred method for coupling to the deprotected 4-(2',4'-dimethoxyphenyl-Fmoc-aminomethyl)phenoxyacetamidoethyl resins are *O*-benzotriazol-1-yl-N,N,N',N'-tetramethyluroniumhexafluorophosphate (HBTU, 1 equiv.) and 1-hydroxybenzotriazole (HOBT, 1 equiv.), or [*O*-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate] (HATU, 1 equiv.)
30 in DMF.

The coupling of successive protected amino acids can be carried out in an automatic polypeptide synthesizer as is well known in the art. In a preferred embodiment, the α-amino function in the amino acids of the growing peptide chain are protected with
35 Fmoc. The removal of the Fmoc protecting group from the N-terminal side of the growing peptide is accomplished by treatment with a secondary amine, preferably piperidine. Each

protected amino acid is then introduced in about 3-fold molar excess and the coupling is preferably carried out in DMF. The coupling agent is normally *O*-benzotriazol-1-yl-N,N,N',N'-tetramethyluroniumhexafluorophosphate (HBTU, 1 equiv.) and 1-hydroxybenzotriazole (HOBt, 1 equiv.) or [*O*-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate] (HATU, 1 equiv.).

At the end of the solid phase synthesis, the polypeptide is removed from the resin and deprotected, either in succession or in a single operation. Removal of the polypeptide and deprotection can be accomplished in a single operation by treating the resin-bound polypeptide with a cleavage reagent, for example trifluoroacetic acid containing thioanisole, water, or ethanedithiol.

In cases wherein the C-terminus of the polypeptide is an alkylamide, the resin is cleaved by aminolysis with an alkylamine. Alternatively, the peptide may be removed by transesterification, e.g. with methanol, followed by aminolysis or by direct transamidation. The protected peptide may be purified at this point or taken to the next step directly. The removal of the side chain protecting groups is accomplished using the cleavage cocktail described above.

The fully deprotected peptide is purified by a sequence of chromatographic steps employing any or all of the following types: ion exchange on a weakly basic resin in the acetate form; hydrophobic adsorption chromatography on underivatized polystyrene-divinylbenzene (for example, AMBERLITE® XAD); silica gel adsorption chromatography; ion exchange chromatography on carboxymethylcellulose; partition chromatography, e.g. on SEPHADEX® G-25, LH-20 or countercurrent distribution; high performance liquid chromatography (HPLC), especially reverse-phase HPLC on octyl- or octadecylsilyl-silica bonded phase column packing.

The foregoing may be better understood in light of the Examples which are meant to describe compounds and process which can be carried out in accordance with the invention and are not intended as a limitation on the scope of the invention in any way.

Abbreviations which have been used the following examples are: NMP for N-methylpyrrolidinone; HBTU for 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; DMF for N,N-dimethylformamide, and TFA for trifluoroacetic acid.

EXAMPLE 1

N-Ac-Sar-Gly-Lys(Ac)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

In the reaction vessel of an Applied Biosystems 433A peptide synthesizer was placed 0.1mM of Fmoc-Pro-Sieber ethylamide resin. Cartridges of 1mM amino acids

were sequentially loaded. The Fastmoc 0.1 with previous peak monitoring protocol was used with the following is the synthetic cycle:

1. Resin solvated with NMP for about 5 minutes;
2. Resin washed with NMP for about 5 minutes;
- 5 3. Fmoc group removed using 50% piperidine solution in NMP for 5 minutes, resin washed, and the sequence repeated 3 to 4 times;
4. Fmoc-amino acid activated with 1mM of 0.5M HBTU in DMF;
5. Activated Fmoc-amino acid added to the reaction vessel followed by addition of 1mM of 2M diisopropylamine in NMP solution;
- 10 6. Fmoc-amino acid coupled for 20 minutes;
7. Resin washed and Fmoc-group removed using 50% piperidine in NMP.

The following protected amino acids were sequentially coupled to the resin using above protocol:

<u>Amino acid</u>	<u>Coupling time</u>
1. Fmoc-Arg(Pmc)	20 minutes
2. Fmoc-Ile	20 minutes
3. Fmoc-Nva	20 minutes
4. Fmoc-Thr(<i>t</i> -Bu)	20 minutes
5. Fmoc-D-Leu	20 minutes
6. Fmoc-Lys(Ac)	20 minutes
7. Fmoc-Gly	20 minutes
8. Fmoc-Sar	20 minutes
9. acetic acid	20 minutes

- 15 Upon completion of the synthesis the resin-bound peptide was washed with methanol three times and dried *in vacuo*, then treated with a (95:5) TFA/water solution (3 mL) at room temperature overnight. The resin was filtered and washed 3 times with methanol. The filtrates and the washes were combined and concentrated *in vacuo*. The residue was treated with ether and the precipitate was filtered to provide the crude peptide
- 20 as an amorphous powder. This was purified by preparative HPLC using a C-18 column with a solvent system increasing in gradient from 5% to 100% acetonitrile/water containing 0.1% TFA over a period of 50 minutes. The pure fractions were lyophilized to

provide N-Ac-Sar-Gly-Lys(Ac)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 2.764$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1065 ($M+H$).

5

EXAMPLE 2

N-Ac-Sar-Gly-Pro-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-Pro for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-Pro-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 3.092$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 992 (M^+).

15

EXAMPLE 3

N-Ac-Sar-Gly-5-BrThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-5-BrThiAla for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-5-BrThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 4.392$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1128 ($M+H$).

25

EXAMPLE 4

N-Ac-Sar-Gly-3-CNPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-3CNPheAla for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-3-CNPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 3.805$ minutes (using a C-18 column and a solvent system increasing in gradient from

35

20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1065 (M⁺).

EXAMPLE 5

N-Ac-Sar-Gly-Cys(Et)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-Cys(Et) for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-Cys(Et)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 3.629 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1024 (M⁺).

EXAMPLE 6

N-Ac-Sar-Gly-3-ThzAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-3-ThzAla for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-3-ThzAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 3.172 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1049 (M⁺).

EXAMPLE 7

N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting (1R,4S)-1-Fmoc-amino-cyclopent-2-ene-4-carboxylic acid for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 2.961 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water

containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1004 (M^+).

EXAMPLE 8

5 N-Ac-Sar-Gly-3,4-diOMePheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-3,4-diOMePheAla for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-3,4-diOMePheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 3.49 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1102 (M^+).

15 EXAMPLE 9

N-Ac-Sar-Gly-4-MePheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-4-MePheAla for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-4-MePheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 4.2 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1056 (M^+).

25

EXAMPLE 10

N-Ac-Sar-Gly-3-CIPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-3-CIPheAla for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-3-CIPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 4.366 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1076 (M^+).

35

EXAMPLE 11

N-Ac-Sar-Gly-2-ThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-3-(thien-2-yl)alanine for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-2-ThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 3.826$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1046 (M^+).

EXAMPLE 12

N-Ac-Sar-Gly-PheGly-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-PheGly for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-PheGly-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 3.73$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1026 (M^+).

EXAMPLE 13

N-Ac-Sar-Gly-2,4-Diabu-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting 4-Boc-amino-2- Fmoc-butanoic acid for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-2,4-Diabu-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 2.50$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 995 (M^+).

EXAMPLE 14

N-Ac-Sar-Gly-Met(O₂)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

09718591.112200

The desired product was prepared by substituting Fmoc-Met(O₂) for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-Met(O₂)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 2.874 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1058 (M⁺).

10

EXAMPLE 15

N-Ac-Sar-Gly-2-Nal-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-2-Nal for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-2-Nal-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 4.56 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1092 (M⁺).

20

EXAMPLE 16

N-Ac-Sar-Gly-1-Nal-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-1-Nal for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-1-Nal-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 4.558 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1092 (M⁺).

30

EXAMPLE 17

N-Ac-Sar-Gly-2-Abu-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-2-Abu for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude

35

peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-2-Abu-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 3.181$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 980 (M^+).

EXAMPLE 18

N-Ac-Sar-Gly-Met(O)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-Met(O) for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-Met(O)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 2.543$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1042 (M^+).

EXAMPLE 19

N-Ac-Sar-Gly-Orn-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc- α -amino-Boc- δ -amino-Orn for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-Orn-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 2.455$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1009 (M^+).

EXAMPLE 20

N-Ac-Sar-Gly-His-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-His(Trt) for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-His-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 2.508$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to

95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1032 (M^+).

EXAMPLE 21

5 N-Ac-Sar-Gly-Trp-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-Trp(Boc) for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-Trp-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 3.912 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1081 (M^+).

15 EXAMPLE 22

N-Ac-Sar-Gly-4-ClPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-4-ClPheAla for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-4-ClPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 4.089 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1076 (M^+).

25

EXAMPLE 23

N-Ac-Sar-Gly-HPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-HPheAla for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-HPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 4.265 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1056 (M^+).

EXAMPLE 24

N-Ac-Sar-Gly-Tic-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-Tic for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin,
5 removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-Tic-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 4.155$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS
10 (ESI) m/e 1054 (M^+).

EXAMPLE 25

N-Ac-Sar-Gly-StyAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-StyAla for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin,
15 removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-StyAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 4.475$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to
20 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1068 (M^+).

EXAMPLE 26

N-Ac-Sar-Gly-Cys(Me)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

25 The desired product was prepared by substituting Fmoc-Cys(Me) for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-Cys(Me)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t =$
30 4.045 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1087 (M^+).

EXAMPLE 27

N-Ac-Sar-Gly-AllylGly-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-AllylGly for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-AllylGly-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 3.33 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 992 (M^+).

EXAMPLE 28

N-Ac-Sar-Gly-Cys(Et)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-Cys(Et) for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-Cys(Et)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 3.629 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1026 (M^+).

EXAMPLE 29

N-Ac-Sar-Gly-4-FPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-4-FPheAla for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-4-FPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 4.053 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1060 (M^+).

EXAMPLE 30

N-Ac-Sar-Gly-2,3-Diapr-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc- α -amino-Boc- β -aminopropionic acid for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis,

cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-2,3-Diapr-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 2.529$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 981 (M^+).

EXAMPLE 31

N-Ac-Sar-Gly-Tyr-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-Tyr(*t*-Bu) for Fmoc-Lys(Ac) and Fmoc-D-Ile for Fmoc-D-Leu in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-Tyr-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 2.99$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1058 ($M+H$).

EXAMPLE 32

N-Ac-Sar-Gly-Met(O₂)-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-Met(O₂) for Fmoc-Lys(Ac) and Fmoc-D-Ile for Fmoc-D-Leu in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-Met(O₂)-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 2.64$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1058 ($M+H$); Amino Acid Anal.: 0.98 Sar; 0.94 Gly; 0.90 Met(O₂); 2.04 Ile; 0.59 Thr; 0.97 Nva; 1.32 Arg; 1.07 Pro.

EXAMPLE 33

N-Ac-Sar-Gly-3-Pal-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-3-Pal for Fmoc-Lys(Ac) and Fmoc-D-Ile for Fmoc-D-Leu in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with

diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-3-Pal-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 2.79$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1043 (M+H); Amino Acid Anal.: 1.00 Sar; 0.95 Gly; 0.89 3Pal; 2.05 Ile; 0.55 Thr; 0.99 Nva; 1.43 Arg; 1.08 Pro.

EXAMPLE 34

N-Ac-Sar-Gly-4-CIPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-4-CIPheAla for Fmoc-Lys(Ac) and Fmoc-D-Ile for Fmoc-D-Leu in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-4-CIPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 4.17$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1076 (M+H); Amino Acid Anal.: 0.97 Sar; 0.96 Gly; 1.20 4CIPheAla; 2.08 Ile; 0.49 Thr; 0.96 Nva; 1.39 Arg; 1.07 Pro.

EXAMPLE 35

N-Ac-Sar-Gly-1-Nal-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-1-Nal for Fmoc-Lys(Ac) and Fmoc-D-Ile for Fmoc-D-Leu in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-1-Nal-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 4.34$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1092 (M+H); Amino Acid Anal.: 1.06 Sar; 0.96 Gly; 2.09 Ile; 0.48 Thr; 1.00 Nva; 1.41 Arg; 1.01 Pro.

EXAMPLE 36

N-Ac-Sar-Gly-2-Nal-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-2-Nal for Fmoc-Lys(Ac) and Fmoc-D-Ile for Fmoc-D-Leu in Example 1. Upon completion of the synthesis,

cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-2-Nal-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 4.36$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1092 (M+H); Amino Acid Anal.: 0.94 Sar; 0.97 Gly; 2.05 Ile; 0.56 Thr; 0.97 Nva; 1.38 Arg; 1.08 Pro.

EXAMPLE 37

N-Ac-Sar-Gly-3-FPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-3FPheAla for Fmoc-Lys(Ac) and Fmoc-D-Ile for Fmoc-D-Leu in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-3-FPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 3.78$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1060 (M+H); Amino Acid Anal.: 1.06 Sar; 0.96 Gly; 1.04 3FPheAla; 2.01 Ile; 0.47 Thr; 1.00 Nva; 1.41 Arg; 1.03 Pro.

EXAMPLE 38

N-Ac-Sar-Gly-HPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-HPheAla for Fmoc-Lys(Ac) and Fmoc-D-Ile for Fmoc-D-Leu in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-HPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 3.70$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1056 (M+H); Amino Acid Anal.: 1.01 Sar; 0.97 Gly; 1.09 HPheAla; 2.11 Ile; 0.49 Thr; 1.03 Nva; 1.39 Arg; 1.09Pro.

EXAMPLE 39

N-Ac-Sar-Gly-4-FPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-4-FPheAla for Fmoc-Lys(Ac) and Fmoc-D-Ile for Fmoc-D-Leu in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-4-FPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 3.89 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1060 (M+H); Amino Acid Anal.: 0.97 Sar; 0.97 Gly; 0.46 4FPheAla; 1.73 Ile; 0.49 Thr; 1.01 Nva; 1.45 Arg; 1.03 Pro.

EXAMPLE 40

N-Ac-Sar-Gly-alloIle-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-alloIle for Fmoc-Lys(Ac) and Fmoc-D-Ile for Fmoc-D-Leu in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-alloIle-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 3.44 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1008 (M+H); Amino Acid Anal.: 1.08 Sar; 0.98 Gly; 2.99 Ile; 0.54 Thr; 1.02 Nva; 1.45 Arg; 1.02 Pro.

EXAMPLE 41

N-Ac-Sar-Gly-Ser(Bzl)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-Ser(Bzl) for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-Ser(Bzl)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 4.171 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1070 (M⁺).

EXAMPLE 42

N-Ac-Sar-Gly-HSer-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-HSer(*t*-Bu) for Fmoc-Lys(Ac) and Fmoc-D-Ile for Fmoc-D-Leu in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-HSer-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 2.4$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 996 (M+H); Amino Acid Anal.: 1.01 Sar; 0.97 Gly; 0.43 HSer; 2.03 Ile; 0.55 Thr; 0.94 Nva; 1.31 Arg; 1.04 Pro.

EXAMPLE 43

N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Ser-Ser-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-(1R,4S)-AmCyeCO for Fmoc-Lys(Ac), Fmoc-Ser(*t*-Bu) for Fmoc-Thr(*t*-Bu) and Fmoc-Ser(*t*-Bu) for Fmoc-Nva in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Ser-Ser-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 2.69$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 978 (M+H)⁺; Amino Acid Anal.: 1.02 Sar; 0.96 Gly; 1.04 Leu; 1.01 Ile; 0.79 Ser; 1.00 Arg; 1.03 Pro.

EXAMPLE 44

N-(6-MeNicotinyI)-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting 6-methylnicotinic acid for acetic acid and Fmoc-(1R,4S)-AmCyeCO for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-(6-MeNicotinyI)-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 3.67$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS

(ESI) m/e 1081 (M+H)⁺; Amino Acid Anal.: 0.98 Sar; 0.97 Gly; 1.02 Leu; 0.51 Thr; 1.03 Nva; 1.01 Ile; 1.05 Arg; 1.02 Pro.

EXAMPLE 45

5 N-Ac-Sar-Gly-D-ThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-D-ThiAla for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-D-ThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 4.03 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1048 (M+H)⁺; Amino Acid Anal.: 0.99 Sar; 0.94 Gly; 1.02 Leu; 0.45 Thr; 0.99 Nva; 1.03 Ile; 1.01 Arg; 1.00 Pro.

15

EXAMPLE 46

N-Ac-Sar-Gly-3CNPheAla-D-Leu-Thr-Nva-Ile-Arg-Pro-DAlaNH₂

The desired product was prepared by substituting Fmoc-DAla-Sieber amide resin for Fmoc-Pro-Sieber ethylamide resin and Fmoc-3CNPheAla for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-3CNPheAla-DLeu-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 3.83 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1110 (M+H)⁺; Amino Acid Anal.: 1.02 Sar; 0.98 Gly; 0.96 Leu; 0.48 Thr; 1.01 Nva; 0.99 Ile; 1.04 Arg; 1.1 Pro; 1.03 Ala.

25

EXAMPLE 47

30 N-Ac-Sar-Gly-D-Val-D-Ile-Thr-Nva-Ile-Arg-ProNH₂

The desired product was prepared by substituting Fmoc-D-Val for Fmoc-Lys(Ac) and Fmoc-D-Ile for Fmoc-D-Leu in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-D-Val-D-Ile-Thr-Nva-Ile-Arg-ProNH₂ as the trifluoroacetate salt; R_t = 3.31 minutes (using a C-18 column and a solvent system

35

increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 994 (M+H)⁺; Amino Acid Anal.: 1.02 Sar; 0.98 Gly; 1.00 Val; 2.10 Ile; 0.44 Thr; 1.03 Nva; 0.93 Arg; 1.03 Pro.

5

EXAMPLE 48

N-Ac-Sar-Gly-ThiAla-D-Leu-Thr-Nva-Ile-Arg-Pro-D-AlaNH₂

The desired product was prepared by substituting Fmoc-DAla-Sieber amide resin for Fmoc-Pro-Sieber ethylamide resin and Fmoc-ThiAla for Fmoc-Lys(Ac) in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-ThiAla-D-Leu-Thr-Nva-Ile-Arg-Pro-DAlaNH₂ as the trifluoroacetate salt; R_t = 3.77 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1091 (M+H)⁺; Amino Acid Anal.: 0.96 Sar; 1.03 Gly; 1.02 Leu; 0.43 Thr; 1.02 Nva; 0.97 Ile; 1.00 Arg; 1.08 Pro.

15

EXAMPLE 49

N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Gln-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-(1R,4S)-AmCyeCO for Fmoc-Lys(Ac) and Fmoc-Gln(Trt) for Fmoc-Nva in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative HPLC to provide N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Gln-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; R_t = 2.78 minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 1033 (M⁺); Amino Acid Anal.: 1.00 Sar; 1.02 Gly; 1.08 Leu; 0.58 Thr; 0.98 Glu; 1.01 Ile; 1.00 Arg; 1.01 Pro.

25

30

EXAMPLE 50

N-Ac-Sar-Gly-D-Val-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl

The desired product was prepared by substituting Fmoc-D-Val for Fmoc-Lys(Ac) and Fmoc-Ile for Fmoc-D-Leu in Example 1. Upon completion of the synthesis, cleavage of the peptide from the resin, removal of the protecting groups, precipitation with diethyl ether, and filtration, the crude peptide was obtained. This was purified by preparative

35


HPLC to provide N-Ac-Sar-Gly-D-Val-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl as the trifluoroacetate salt; $R_t = 3.90$ minutes (using a C-18 column and a solvent system increasing in gradient from 20% to 95% acetonitrile/water containing 10mM ammonium acetate over a period of 10 minutes); MS (ESI) m/e 993 (M^+); Amino Acid Anal.: 0.94 Sar; 0.97 Gly; 1.07 Val; 1.88 Ile; 0.51 Thr; 1.10 Nva; 1.02 Arg; 1.06 Pro.

It will be evident to one skilled in the art that the instant invention is not limited to the foregoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims and therefore intended to be embraced therein.

002217-16537460

WHAT IS CLAIMED IS:

1. A compound of formula (I)



- 5 or a pharmaceutically acceptable salt thereof, wherein

Xaa₁ is absent or Xaa₁ is selected from the group consisting of hydrogen and an acyl group, wherein the acyl group is selected from the group consisting of

- 10 $\text{R}^1\text{-(CH}_2\text{)}_n\text{-C(O)-}$, wherein n is an integer from 0 to 8 and R¹ is selected from the group consisting of N-acetylamino, alkoxy, alkyl, aryl, carboxy, cycloalkenyl, cycloalkyl, heterocycle, hydroxy; and
 $\text{R}^2\text{-CH}_2\text{CH}_2\text{-O-(CH}_2\text{CH}_2\text{O)}_p\text{-CH}_2\text{-C(O)-}$, wherein p is an integer from 1 to 8 and R² is selected from the group consisting of hydrogen, N-acetylamino, and alkyl;

- 15 Xaa₂ is an amino acyl residue selected from the group consisting of

- alanyl,
β-alanyl,
asparaginyl,
citrullyl,
20 N-ethylglycyl,
glutaminyl,
glutamyl,
methionyl,
N-methylalanyl,
25 N-methylprolyl,
prolyl,
pyro-glutamyl,
sarcosyl,
seryl,
30 threonyl,

$\text{H}_3\text{C-C(O)-HN-(CH}_2\text{)}_q\text{-C(O)-}$, wherein q is an integer from 1 to 8, and

$\text{H}_3\text{C-C(O)-HN-CH}_2\text{CH}_2\text{-O-(CH}_2\text{CH}_2\text{O)}_r\text{-CH}_2\text{-C(O)-}$, wherein r is an integer from 1 to 8;

- 35 with the proviso that Xaa₁ is absent when Xaa₂ is N-methylprolyl, $\text{H}_3\text{C-C(O)-HN-(CH}_2\text{)}_q\text{-C(O)-}$, or $\text{H}_3\text{C-C(O)-HN-CH}_2\text{CH}_2\text{-O-(CH}_2\text{CH}_2\text{O)}_r\text{-CH}_2\text{-C(O)-}$;

Xaa₃ is an amino acyl residue selected from the group consisting of
 alanyl,
 asparaginylyl,
 40 aspartyl,
 glutaminylyl,
 glutamyl,
 glycyl,
 leucyl,
 45 methionyl,
 phenylalanyl,
 prolyl, and
 seryl;

Xaa₄ is an amino acyl residue selected from the group consisting of
 alloisoleucyl,
 allylglycyl,
 2-aminobutyryl,
 (1R,4S)-1-aminocyclopent-2-ene-4-carbonyl,
 55 aspartyl,
 3-(5-bromothiophen-2-yl)alanyl,
 3-(3-chlorophenyl)alanyl,
 3-(4-chlorophenyl)alanyl,
 3-(3-cyanophenyl)alanyl,
 60 cysteinyl(S-ethyl),
 cysteinyl(S-methyl),
 2,4-diaminobutanoyl,
 2,3-diaminopropionyl,
 3-(3,4-dimethoxyphenyl)alanyl,
 65 3-(3-fluorophenyl)alanyl,
 3-(4-fluorophenyl)alanyl,
 histidyl,
 homophenylalanyl,
 homoseryl,
 70 lysyl(N-epsilon-acetyl),
 methionyl(sulfone),
 methionyl(sulfoxide),

- 75 3-(4-methylphenyl)alanyl,
3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
ornithyl,
phenylglycyl,
prolyl,
3-(3-pyridyl)alanyl,
80 seryl(benzyl),
styrylalanyl,
1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
3-(thiazolyl)alanyl,
3-(thien-2-yl)alanyl,
85 D-3-(thien-2-yl)alanyl,
tryptyl,
tyrosyl, and
D-valyl;
- 90 Xaa₅ is an amino acyl residue selected from the group consisting of
D-alanyl,
alloisoleucyl,
D-alloisoleucyl,
D-allothreonyl,
95 D-allylglycyl,
D-2-aminobutyryl,
D-3-(4-aminophenyl)alanyl,
D-asparaginyll,
D-aspartyl,
100 D-3-(4,4'-biphenyl)alanyl,
D-*t*-butylglycyl,
D-3-(4-chlorophenyl)alanyl,
D-citrullyl,
D-3-(3-cyanophenyl)alanyl,
105 D-cyclohexylalanyl,
D-cyclohexylglycyl,
D-cysteinyl,
D-cysteinyl(S-*t*-butyl),

110	dehydroleucyl, D-3-(3,4-difluorophenyl)alanyl, D-3-(3,4-dimethoxyphenyl)alanyl, D-glutaminy, D-glutamyl, glycyl,
115	D-histidyl, D-homoisoleucyl, D-homophenylalanyl, D-homoseryl, isoleucyl,
120	D-isoleucyl, D-leucyl, D-lysyl, D-lysyl(N-epsilon-nicotinyl), D-methionyl,
125	D-3-(4-methylphenyl)alanyl, D-3-(naphth-1-yl)alanyl, D-3-(naphth-2-yl)alanyl, D-neopentylglycyl, D-3-(4-nitrophenyl)alanyl,
130	D-norleucyl, D-norvalyl, D-ornithyl, D-penicillaminy, D-penicillaminy(S-acetamidomethyl),
135	D-penicillaminy(S-benzyl), D-penicillaminy(S-methyl), D-phenylalanyl, prolyl, D-prolyl,
140	D-3-(3-pyridyl)alanyl, D-seryl, D-seryl(O-benzyl), D-3-(thien-2-yl)alanyl, D-threonyl,

145 D-threonyl(O-benzyl),
D-3-(3-trifluoromethylphenyl)alanyl,
D-3-(3,4,5-trifluorophenyl)alanyl,
D-tryptyl,
D-tyrosyl(O-benzyl),
150 D-tyrosyl(O-ethyl),
D-tyrosyl, and
D-valyl;

Xaa₆ is an amino acyl residue selected from the group consisting of

155 alanyl,
allothreonyl,
D-allothreonyl,
allylglycyl,
asparaginy,
160 cysteiny,
glutaminy,
glycyl,
histidy,
homoseryl,
165 D-homoseryl,
3-(4-hydroxymethylphenyl)alanyl,
isoleucyl,
lysyl(N-epsilon-acetyl),
methionyl,
170 3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
norvalyl,
octylglycyl,
ornithyl,
175 penicillaminy,
prolyl,
3-(3-pyridyl)alanyl,
seryl,
D-seryl,
180 threonyl,

D-threonyl,
tryptyl, and
tyrosyl;

185 Xaa₇ is an amino acyl residue selected from the group consisting of
alanyl,
allylglycyl,
2-aminobutyryl,
arginyl,
190 asparaginylyl,
aspartyl,
3-(4-carboxyamidophenyl)alanyl,
citruillyl,
cyclohexylalanyl,
195 cysteinylyl,
glutaminylyl,
D-glutaminylyl,
glutamyl,
glycyl,
200 histidylyl,
homoalanyl,
homoleucyl,
homoseryl,
D-homoseryl,
205 isoleucyl,
leucyl,
D-leucyl,
lysyl(N-epsilon-acetyl),
lysyl(N-epsilon-isopropyl),
210 methionyl(sulfone),
methionyl(sulfoxide),
methionyl,
3-(naphth-1-yl)alanyl,
D-3-(naphth-1-yl)alanyl,
215 3-(naphth-2-yl)alanyl,
D-3-(naphth-2-yl)alanyl,

255 penicillaminyl,
phenylalanyl,
prolyl,
seryl,
tryptyl,
tyrosyl, and
valyl;

260

Xaa₉ is an amino acyl residue selected from
[(4-amino(N-isopropyl)methyl)phenyl]alanyl,
3-(4-amino-N-isopropylphenyl)alanyl,
arginyl,
265 arginyl(N^GN^{G'}diethyl),
citrullyl,
3-(cyclohexyl)alanyl(4-N-isopropyl),
glycyl[4-piperidinyl(N-amidino)],
(3-guanidino)alanyl,
270 3-(4-guanidinophenyl)alanyl,
histidyl,
homoarginyl,
lysyl,
lysyl(N-epsilon-isopropyl),
275 lysyl(N-epsilon-nicotinyl),
norarginyl,
ornithyl(N-delta-isopropyl),
ornithyl(N-delta-nicotinyl),
ornithyl[N-delta-(2-imidazolinyl)],
280 [4-piperidinyl(N-amidino)]alanyl, and
[3-pyrrolidinyl(2-N-amidino)]alanyl;


Xaa₁₀ is an amino acyl residue selected from the group consisting of
D-alanyl,
285 2-aminobutyryl,
2-aminoisobutyryl,
t-butylglycyl,
homoprolyl,

290 hydroxypropyl,
 isoleucyl,
 leucyl,
 phenylalanyl,
 prolyl,
 D-prolyl,
 295 seryl,
 1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
 threonyl, and
 valyl;

300 Xaa₁₁ is a hydroxy group or an amino acid amide selected from the group consisting of

D-alanylamide,
 D-alanylethylamide,
 azaglycylamide,
 305 glycylamide,
 glycylethylamide,
 sarcosylamide,
 serylamide,
 D-serylamide,

310 a residue represented by the formula



a group represented by the formula -NH-R^5 ; wherein

s is an integer selected from 0 to 8;

315 R³ is selected from the group consisting of hydrogen, alkyl, and a 5- to 6-membered cycloalkyl ring;

R⁴ is selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, cycloalkenyl, cycloalkyl, heterocycle, and hydroxy;

provided that s is not zero when R⁴ is hydroxy or alkoxy; and

R⁵ is selected from hydrogen, hydroxy, and cycloalkyl.

320

2. A compound according to Claim 1, wherein Xaa₁ is absent or is selected from the group consisting of
 hydrogen,

5 acetyl,
N-acetyl- β -alanyl,
(4-N-acetylamino)butyryl,
(6-N-acetylamino)caproyl,
(8-N-acetylamino)-3,6-dioxo-octanoyl,
10 butyryl,
caproyl,
5-chloro-2-hydroxynicotinyl,
5-chloro-6-hydroxynicotinyl,
2-chloroisonicotinyl,
2-chloro-6-methylnicotinyl,
15 cyclohexylacetyl,
furoyl,
2-hydroxy-6-methylnicotinyl,
6-hydroxynicotinyl,
6-hydroxy-2-picolinyl,
20 isonicotinyl,
2-methoxyacetyl,
2-methylnicotinyl,
6-methylnicotinyl,
(4-methyl)phenylacetyl,
25 nicotinyl,
phenylacetyl,
propionyl,
shikimyl,
succinyl, and
30 tetrahydrofuroyl.

3. A compound according to Claim 2 wherein Xaa₁ is selected from the group consisting of

acetyl, and
6-methylnicotinyl.

5

4. A compound according to Claim 1 wherein Xaa₂ is selected from the group consisting of

alanyl,

5 β-alanyl,
 asparaginylyl,
 citrullyl,
 N-ethylglycyl,
 glutaminyl,
 glutamyl,
 10 methionyl,
 N-methylalanyl,
 N-methylprolyl,
 prolyl,
 pyro-glutamyl,
 15 sarcosyl,
 seryl,
 threonyl,
 H₃C-C(O)-HN-(CH₂)_q-C(O)-, wherein q is an integer from 1 to 8, and
 H₃C-C(O)-HN-CH₂CH₂-O-(CH₂CH₂O)_r-CH₂-C(O)-, wherein r is an integer
 20 from 1 to 8.

5. A compound according to Claim 4, wherein Xaa₂ is sarcosyl.

6. The compound according to Claim 1 wherein Xaa₃ is selected from the group consisting of

5 alanyl,
 asparaginylyl,
 aspartyl,
 glutaminyl,
 glutamyl,
 glycyl,
 leucyl,
 10 methionyl,
 phenylalanyl,
 prolyl, and
 seryl.

7. A compound according to Claim 6 wherein Xaa₃ is glycyl.

8. A compound according to Claim 1 wherein Xaa₄ is selected from the group consisting of

- alloisoleucyl,
- allylglycyl,
- 5 2-aminobutyryl,
- (1R,4S)-1-aminocyclopent-2-ene-4-carbonyl,
- aspartyl,
- 3-(5-bromothiophen-2-yl)alanyl,
- 3-(3-chlorophenyl)alanyl,
- 10 3-(4-chlorophenyl)alanyl,
- 3-(3-cyanophenyl)alanyl,
- cysteinyl(S-ethyl),
- cysteinyl(S-methyl),
- 2,4-diaminobutanoyl,
- 15 2,3-diaminopropionyl,
- 3-(3,4-dimethoxyphenyl)alanyl,
- 3-(3-fluorophenyl)alanyl,
- 3-(4-fluorophenyl)alanyl,
- histidyl,
- 20 homophenylalanyl,
- homoseryl,
- lysyl(N-epsilon-acetyl),
- methionyl(sulfone),
- methionyl(sulfoxide),
- 25 3-(4-methylphenyl)alanyl,
- 3-(naphth-1-yl)alanyl,
- 3-(naphth-2-yl)alanyl,
- ornithyl,
- phenylglycyl,
- 30 prolyl,
- 3-(3-pyridyl)alanyl,
- seryl(O-benzyl),
- styrylalanyl,
- 1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
- 35 3-(thiazolyl)alanyl,
- 3-(thien-2-yl)alanyl,

002211 6587260

40 D-3-(thien-2-yl)alanyl,
tryptyl,
tyrosyl, and
D-valyl.

9. A compound according to Claim 8 wherein Xaa₄ is selected from the group consisting of

5 alloisoleucyl,
allylglycyl,
2-aminobutyryl,
(1R,4S)-1-aminocyclopent-2-ene-4-carbonyl,
3-(5-bromothien-2-yl)alanyl,
3-(3-chlorophenyl)alanyl,
3-(4-chlorophenyl)alanyl,
10 3-(3-cyanophenyl)alanyl,
cysteinyl(S-ethyl),
cysteinyl(S-methyl),
2,4-diaminobutanoyl,
2,3-diaminopropionyl,
15 3-(3,4-dimethoxyphenyl)alanyl,
3-(3-fluorophenyl)alanyl,
3-(4-fluorophenyl)alanyl,
histidyl,
homophenylalanyl,
20 homoseryl,
lysyl(N-epsilon-acetyl),
methionyl(sulfone),
methionyl(sulfoxide),
3-(4-methylphenyl)alanyl,
25 3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
ornithyl,
phenylglycyl,
prolyl,
30 3-(3-pyridyl)alanyl,
seryl(O-benzyl),

styrylalanyl,
1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
3-(thiazolyl)alanyl,
35 3-(thien-2-yl)alanyl,
D-3-(thien-2-yl)alanyl,
tryptyl,
tyrosyl, and
D-valyl.

40

10. A compound according to Claim 1, wherein Xaa₅ is selected from the group consisting of

D-alanyl,
alloisoleucyl,
5 D-alloisoleucyl,
D-allothreonyl,
D-allylglycyl,
D-2-aminobutyryl,
D-3-(4-aminophenyl)alanyl,
10 D-asparaginy, l,
D-aspartyl,
D-3-(4,4'-biphenyl)alanyl,
D-*t*-butylglycyl,
D-3-(4-chlorophenyl)alanyl,
15 D-citrullyl,
D-3-(3-cyanophenyl)alanyl,
D-cyclohexylalanyl,
D-cyclohexylglycyl,
D-cysteiny, l,
20 D-cysteiny, l(S-*t*-butyl),
dehydroleucyl,
D-3-(3,4-difluorophenyl)alanyl,
D-3-(3,4-dimethoxyphenyl)alanyl,
D-glutaminy, l,
25 D-glutamyl,
glycyl,
D-histidyl,

30 D-homoisoleucyl,
 D-homophenylalanyl,
 D-homoseryl,
 isoleucyl,
 D-isoleucyl,
 D-leucyl,
 D-lysyl,
 35 D-lysyl(N-epsilon-nicotinyl),
 D-methionyl,
 D-3-(4-methylphenyl)alanyl,
 D-3-(naphth-1-yl)alanyl,
 D-3-(naphth-2-yl)alanyl,
 40 D-neopentylglycyl,
 D-3-(4-nitrophenyl)alanyl,
 D-norleucyl,
 D-norvalyl,
 D-ornithyl,
 45 D-penicillaminy,
 D-penicillaminy(S-acetamidomethyl),
 D-penicillaminy(S-benzyl),
 D-penicillaminy(S-methyl),
 D-phenylalanyl,
 50 prolyl,
 D-prolyl,
 D-3-(3-pyridyl)alanyl,
 D-seryl,
 D-seryl(O-benzyl),
 55 D-3-(thien-2-yl)alanyl,
 D-threonyl,
 D-threonyl(O-benzyl),
 D-3-(3-trifluoromethylphenyl)alanyl,
 D-3-(3,4,5-trifluorophenyl)alanyl,
 60 D-tryptyl,
 D-tyrosyl(O-benzyl),
 D-tyrosyl(O-ethyl),
 D-tyrosyl, and

D-valyl.

65

11. A compound according to Claim 10 wherein Xaa₅ is selected from the group consisting of

isoleucyl,
D-isoleucyl, and
5 D-leucyl.

12. A compound according to Claim 1 wherein Xaa₆ is selected from the group consisting of

alanyl,
allothreonyl,
5 D-allothreonyl,
allylglycyl,
asparaginy,
cysteiny,
glutaminy,
10 glycyl,
histidyl,
homoseryl,
D-homoseryl,
3-(4-hydroxymethylphenyl)alanyl,
15 isoleucyl,
lysyl(N-epsilon-acetyl),
methionyl,
3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
20 norvalyl,
octylglycyl,
ornithyl,
penicillaminy,
prolyl,
25 3-(3-pyridyl)alanyl,
seryl,
D-seryl,
threonyl,

30 D-threonyl,
tryptyl, and
tyrosyl.

13. A compound according to Claim 12 wherein Xaa₆ is selected from the group consisting of

seryl, and
threonyl.

5

14. A compound according to Claim 1 wherein Xaa₇ is selected from the group consisting of

alanyl,
allylglycyl,
5 2-aminobutyryl,
arginyl,
asparaginy, aspartyl,
3-(4-carboxyamidophenyl)alanyl,
10 citrullyl,
cyclohexylalanyl,
cysteinyl,
glutaminy, D-glutaminy,
15 glutamyl,
glycyl,
histidyl,
homoalanyl,
homoleucyl,
20 homoseryl,
D-homoseryl,
isoleucyl,
leucyl,
D-leucyl,
25 lysyl(N-epsilon-acetyl),
lysyl(N-epsilon-isopropyl),
methionyl(sulfone),

002217-15587460

methionyl(sulfoxide),
methionyl,
30 3-(naphth-1-yl)alanyl,
D-3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
D-3-(naphth-2-yl)alanyl,
norleucyl,
35 norvalyl,
D-norvalyl,
octylglycyl,
penicillaminy,
phenylalanyl,
40 propargylglycyl,
3-(3-pyridyl)alanyl,
seryl,
D-seryl,
threonyl,
45 tryptyl,
tyrosyl, and
valyl.

15. A compound according to Claim 14 wherein Xaa₇ is selected from the group consisting of

glutaminy,
norvalyl, and
5 seryl.

16. A compound according to Claim 1 wherein Xaa₈ is selected from the group consisting of

alanyl,
alloisoleucyl,
5 D-alloisoleucyl,
allylglycyl,
aspartyl,
t-butylglycyl,
citrullyl,

10 cyclohexylglycyl,
 cysteinyl,
 glutamyl,
 glycyl,
 homoseryl,
 15 isoleucyl,
 D-isoleucyl,
 leucyl,
 lysyl(N-epsilon-acetyl),
 methionyl,
 20 3-(naphth-1-yl)alanyl,
 3-(naphth-2-yl)alanyl,
 norvalyl,
 penicillaminy,
 phenylalanyl,
 25 prolyl,
 seryl,
 tryptyl,
 tyrosyl, and
 valyl.

30

17. A compound according to Claim 16 wherein Xaa₈ is isoleucyl.

18. A compound according to Claim 1 wherein Xaa₉ is selected from the group consisting of

[(4-amino(N-isopropyl)methyl)phenyl]alanyl,
 3-(4-amino-N-isopropylphenyl)alanyl,
 5 arginyl,
 arginyl(N^GN^{G'}diethyl),
 citrullyl,
 3-(cyclohexyl)alanyl(4-N-isopropyl),
 glycyl[4-piperidinyl(N-amidino)],
 10 (3-guanidino)alanyl,
 3-(4-guanidinophenyl)alanyl,
 histidyl,
 homoarginyl,

09718591 "112200

lysyl,
15 lysyl(N-epsilon-isopropyl),
lysyl(N-epsilon-nicotinyl),
norarginyl,
ornithyl(N-delta-isopropyl),
ornithyl(N-delta-nicotinyl),
20 ornithyl[N-delta-(2-imidazoliny)],
[4-piperidiny](N-amidino)alanyl, and
[3-pyrrolidiny](2-N-amidino)alanyl.

19. A compound according to Claim 18 wherein Xaa₉ is arginyl.

20. A compound according to Claim 1 wherein Xaa₁₀ is selected from the group consisting of

5 D-alanyl,
2-aminobutyryl,
2-aminoisobutyryl,
t-butylglycyl,
homopropyl,
hydroxypropyl,
isoleucyl,
10 leucyl,
phenylalanyl,
prolyl,
D-prolyl,
seryl,
15 1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
threonyl, and
valyl.

21. A compound according to Claim 20 wherein Xaa₁₀ is prolyl.

22. A compound according to Claim 1 wherein Xaa₁₁ is selected from the group consisting of

D-alanylamide,
D-alanylethylamide,

5 azaglycylamide,
 NH-cyclobutyl,
 NH-cycloheptyl,
 NH-1-(cyclohexyl)ethyl,
 NH-2-(cyclohexyl)ethyl,
 10 NH-2-(ethoxy)ethyl,
 NH-ethyl,
 glycylamide,
 glycylethylamide,
 NH-hexyl,
 15 NH-2-(hydroxy)ethyl,
 NH-isoamyl,
 NH-isobutyl,
 NH-2-(isopropoxy)ethyl,
 NH-isopropyl,
 20 NH-2-(methoxy)ethyl,
 NH-3-(methoxy)propyl,
 NH-propyl,
 NH-2-(1-pyrrolidine)ethyl,
 sarcosylamide,
 25 serylamine, and
 D-serylamine.

23. A compound according to Claim 22 wherein Xaa₁₁ is selected from the group consisting of
 D-alanylamine, and
 NH-ethyl.

5
 24. A compound according to Claim 1 wherein

Xaa₁ is selected from the group consisting of
 acetyl, and
 5 6-methylnicotinyl;

Xaa₂ is sarcosyl;

Table 1. Demographic characteristics of the study population	
Age	
Mean (SD)	65.2 (10.5)
Range	45-85
Sex	
Male	55 (55%)
Female	45 (45%)
Ethnicity	
White	60 (60%)
Black	20 (20%)
Hispanic	15 (15%)
Other	5 (5%)
Education	
High school or less	30 (30%)
Some college	25 (25%)
College graduate	20 (20%)
Postgraduate	10 (10%)
Income	
<\$10,000	15 (15%)
\$10,000-\$20,000	20 (20%)
\$20,000-\$30,000	25 (25%)
>\$30,000	20 (20%)
Marital status	
Married	40 (40%)
Single	15 (15%)
Divorced	10 (10%)
Widowed	15 (15%)
Health status	
Good	30 (30%)
Fair	25 (25%)
Poor	10 (10%)
Comorbidities	
Hypertension	40 (40%)
Diabetes	20 (20%)
Cholesterol	30 (30%)
Arthritis	25 (25%)
Depression	15 (15%)
Medication use	
0-2	10 (10%)
3-5	20 (20%)
>5	30 (30%)
Healthcare utilization	
Regular visits	30 (30%)
Emergency visits	10 (10%)
Hospitalizations	5 (5%)
Health insurance	
Medicare	40 (40%)
Medicaid	20 (20%)
Private	15 (15%)
Uninsured	5 (5%)

15

20

25

30

35

40

Xaa₄ is selected from the group consisting of
alloisoleucyl,
allylglycyl,
2-aminobutyryl,
(1R,4S)-1-aminocyclopent-2-ene-4-carbonyl,
3-(5-bromothiophen-2-yl)alanyl,
3-(3-chlorophenyl)alanyl,
3-(4-chlorophenyl)alanyl,
3-(3-cyanophenyl)alanyl,
cysteinyl(S-ethyl),
cysteinyl(S-methyl),
2,3-diaminopropionyl,
2,4-diaminobutanoyl,
3-(3,4-dimethoxyphenyl)alanyl,
3-(3-fluorophenyl)alanyl,
3-(4-fluorophenyl)alanyl,
histidyl,
homophenylalanyl,
homoseryl,
lysyl(N-epsilon-acetyl),
methionyl(sulfone),
methionyl(sulfoxide),
3-(4-methylphenyl)alanyl,
3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
ornithyl,
phenylglycyl,
prolyl,
3-(3-pyridyl)alanyl,
seryl(O-benzyl),
styrylalanyl,
1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
3-(thiazolyl)alanyl,
3-(thien-2-yl)alanyl,

45 D-3-(thien-2-yl)alanyl,
tryptyl,
tyrosyl, and
D-valyl,

50 Xaa₅ is selected from the group consisting of
isoleucyl,
D-isoleucyl, and
D-leucyl;

55 Xaa₆ is selected from the group consisting of
seryl, and
threonyl;

60 Xaa₇ is selected from the group consisting of
glutaminy, and
norvalyl, and
seryl;

65 Xaa₈ is isoleucyl;

Xaa₉ is arginyl;

Xaa₁₀ is prolyl; and

70 Xaa₁₁ is selected from the group consisting of
D-alanylamine, and
NH-ethyl.

25. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

26. A method of treating a patient in need of anti-angiogenesis therapy comprising administering to the patient in need a therapeutically effective amount of a compound of Claim 1.

27. A composition for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention, macular degeneration and diabetic retinopathy comprising a compound of Claim 1 in combination with a pharmaceutically acceptable carrier.

5

28. A method of isolating a receptor from an endothelial cell comprising binding a compound of Claim 1 to the receptor to form a peptide receptor complex; isolating the peptide receptor complex; and purifying the receptor.

29. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of

N-Ac-Sar-Gly-5-BrThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-2-Nal-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

5 N-Ac-Sar-Gly-Orn-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-4-ClPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-HPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-Cys(Me)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-Cys(Et)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl, and

10 N-Ac-Sar-Gly-Tyr-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl.

30. A compound, or a therapeutically acceptable salt thereof, selected from the group consisting of

N-Ac-Sar-Gly-Lys(Ac)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-Pro-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

5 N-Ac-Sar-Gly-3-CNPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-Cys(Et)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-4-ThzAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-3,4-diOMePheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

10 N-Ac-Sar-Gly-4-MePheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-3-ClPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-2-ThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-PheGly-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-2,4-Diabu-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,


15 N-Ac-Sar-Gly-Met(O₂)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-1-Nal-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

- N-Ac-Sar-Gly-2-Abu-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-Met(O)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-His-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 20 N-Ac-Sar-Gly-Trp-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-Tic-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-StyAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-AllylGly-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-4-FPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 25 N-Ac-Sar-Gly-2,3-Diapr-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-Met(O₂)-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl
 N-Ac-Sar-Gly-3-PyrAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-4-ClPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-1-Nal-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl
 30 N-Ac-Sar-Gly-2-Nal-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-3-FPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-HPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-4-FPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-alloIle-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 35 N-Ac-Sar-Gly-Ser(Bzl)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-HSer-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Ser-Ser-Ile-Arg-ProNH-ethyl,
 N-6MeNic-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-2-ThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 40 N-Ac-Sar-Gly-3-CNPhe-D-Leu-Thr-Nva-Ile-Arg-Pro-D-AlaNH₂,
 N-Ac-Sar-Gly-D-Val-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-D-2-ThiAla-D-Leu-Thr-Nva-Ile-Arg-Pro-D-AlaNH₂,
 N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Gln-Ile-Arg-ProNH-ethyl, and
 N-Ac-Sar-Gly-D-Val-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl.

Abstract

Peptides of formula (I)



5

are useful for inhibiting angiogenesis. Also disclosed are angiogenesis-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.